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Abstract 
 
Melanoma 'risk' is multifaceted, with genetic, phenotypic, and environmental factors all 
contributing to melanoma predisposition. Although the majority of melanoma is attributable to 
random acquired mutations in melanocytes, a positive family history is associated with an increased 
risk of developing the disease, and the presence of heritable germline variants is an important 
component of melanoma susceptibility for some families. Mutation in one of the known high 
penetrance melanoma predisposition genes, comprising CDKN2A, CDK4, BAP1, POT1, ACD, 
TERF2IP, and TERT, underpins melanoma risk for approximately half of all high-density familial 
clustering of melanoma. However, the underlying genetic basis of disease remains unexplained for 
many families. 
 
It is likely that a polygenic component to melanoma predisposition accounts for the remainder of 
families, where overall susceptibility is influenced by combinations of low to moderate risk 
polymorphisms, rare high penetrance germline mutations, and modulation of risk by environmental 
and genetic factors. Although no single presently known germline alteration guarantees disease 
development, the main impact of predisposition genes is the elevation of baseline melanoma risk. 
For an individual with existing genetic susceptibility, it is likely that fewer sporadic mutations are 
required to accumulate before a critical level for oncogenesis is reached. Beyond conferring risk of 
cutaneous melanoma, some ‘melanoma’ predisposition genes have been linked to diverse cancer 
phenotypes. Familial risk has been proposed as a shared feature of many cancers, and clustering of 
additional cancers in melanoma families has been observed at rates greater than expected by 
chance. 
 
In a cohort of 178 'intermediate risk' melanoma families, cancer development was assessed over a 
33 year period, and identified significantly more than expected bladder cancer, lymphoid 
leukaemia, and myeloma. Further to population level cancer risk, it is proposed that some cancer 
dense families carry known and possibly as-yet-unidentified melanoma predisposition genes. 
 
Eight families with high melanoma case density and eleven individuals with three or more invasive 
cancer types including melanoma were selected for further follow up with whole exome or whole 
genome sequencing. Multiple damaging variants in cancer-associated genes were identified, 
supporting a polygenic basis for melanoma susceptibility. Given the diversity of genetic variants 
and other cancer types in the cohort, it is possible that some cancer-associated genes identified here 
also have pleiotropic effects in predisposing to melanoma.
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Chapter 1 
 
Introduction 
 
This project aims to assess melanoma risk genes and development of other cancers in a population 
based sample of Queensland melanoma cases and their families. The study cohort comprises 178 
families originally ascertained as part of the Queensland Familial Melanoma Project (QFMP), 
designated as ‘intermediate risk’ due to confirmed primary melanoma in two first-degree relatives, 
diagnosed between 1982 and 1990. Of the ‘intermediate risk’ group, these 178 families had not had 
further contact since a follow up study (The Queensland Study of Melanoma: environmental and 
genetic associations (Q-MEGA)) was completed between 2002 and 2005, when one or more 
individuals in each family answered a telephone interview relating to personal and family cancer 
information. 
 
Follow up was conducted of these 178 families to determine all new occurrences of melanoma and 
other cancers, as validated by Queensland Cancer Registry and pathology records. Testing of existing 
saliva DNA samples enabled genetic analysis of the families, with further exome sequencing for 
families with a high melanoma case density and overall cancer burden. 
 
Known high penetrance mutations predisposing to melanoma account for only approximately half of 
all familial clustering, and it is hypothesised that a number of other high penetrance risk genes exist. 
Additionally, since some ‘melanoma’ risk genes are associated with the development of other cancers, 
it is hypothesised that other novel high-penetrance melanoma risk genes also predispose to other 
cancer types. Therefore this study aims to address the specific hypotheses that: 
 
1. Known melanoma predisposition genes are associated with the development of melanoma in a 
cohort of ‘intermediate’ risk families, i.e. those of relatively low case density. 
2. Novel high-penetrance germline melanoma genes associated with development of melanoma 
have yet to be identified. 
3. Some high-penetrance melanoma genes are associated with the development of other cancers. 
4. Additional cancer types may be over-represented in ‘melanoma’ families due to underlying 
predisposition to cancer conferred by multiple low penetrance alleles and environmental 
modifiers.
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Chapter 2 
 
Familial melanoma genetics and links with other cancers 
 
Read J, Wadt K, Hayward N. Melanoma Genetics. J Med Genet. 2016;53:1-16. 
 
Relevance to thesis aims 
 
This chapter relates to all four thesis aims, by exploring the existing genetic landscape of familial 
melanoma and also seeking to identify new genes in the literature that may be associated with 
melanoma development. For thesis aim 1, this chapter discusses known melanoma predisposition 
genes, and relates to thesis aim 2 by exploring novel research evidence and putative melanoma 
predisposition genes, enabling these genes of interest to be prioritised during the next generation 
sequencing stage of the project. A focus on additional cancers linked to ‘melanoma’ predisposition 
genes and review of low to moderate penetrance alleles relate to aims 3 and 4 respectively. 
 
This chapter was initially prepared and written with the intention of it forming the first chapter of 
the thesis, and subsequently was submitted for publication. It represents an overview of familial 
melanoma, existing links with other cancers, and a polygenic basis of disease that ‘sets the scene’ 
for detailed exploration of these topics in a cohort of melanoma families. 
 
Contribution of candidate 
 
I prepared the manuscript and all figures and tables. I created figures 1, 4, and 5 in Microsoft 
powerpoint, and composed figures 2 and 3 from supplied clinical photographs. 
 
Acknowledgement of the contribution of others 
 
Supervisor Prof Nicholas Hayward reviewed and edited all draft versions of the manuscript. Dr 
Karin Wadt sourced clinical photographs used in figure 2 and figure 3, and supplied comments on 
the final manuscript. Dr Kiarash Khosrotehrani kindly assisted with the descriptions of dermoscopic 
features for figures 2 and 3. Dr Matthew Law conducted statistical analysis of low penetrance risk 
loci in Table 1. 
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INTRODUCTION 
 
The concept of melanoma risk is dynamic and multi-faceted, owing to the diverse aetiology and 
heterogeneous nature of the disease. Genetic, phenotypic, and environmental risk factors all 
contribute to melanoma predisposition. The majority of alterations underlying the genetic basis of 
this disease occur as random acquired mutations within melanocytes, and an accumulation of 
genomic changes contribute to melanoma development, progression, and evolution. However, the 
presence of heritable germline variants is an important component of melanoma susceptibility.1 
Genes that predispose to melanoma are typically grouped into low, medium, and high penetrance 
genes.2 Penetrance relates to the likelihood of a mutation carrier developing the disease over time, 
and reflects the overall contribution of a specific gene polymorphism, or mutation, to melanoma 
risk. Although no single presently known germline alteration guarantees melanoma development, 
the main impact of predisposition genes is the elevation of baseline melanoma risk. For an 
individual with moderate to high genetic susceptibility, it is likely that fewer somatic mutations are 
required to accumulate before a critical level for oncogenesis is reached. Additionally, melanoma 
risk genes may interact directly with other genes or environmental risk factors to influence and 
activate melanoma growth pathways.1, 3 
 
A positive family history is associated with an increased risk of developing melanoma, and is 
particularly significant when there is a first-degree relative with multiple primary melanomas, or 
single primary melanomas in two or more first-degree relatives.1 The most common gene 
implicated in familial melanoma is cyclin-dependent kinase inhibitor 2A (CDKN2A), accounting for 
predisposition in approximately 20-40% of melanoma families.1 Despite a handful of other known 
high penetrance genes, many cases of familial melanoma are not accounted for molecularly, and the 
genetic basis for susceptibility remains unexplained for a large percentage of families. This suggests 
a likely polygenic mechanism of inheritance, including multiple low-risk alleles and genetic 
modifiers, as well as the possibility of rare mutations in other high-penetrance genes yet to be 
discovered.  The risk genes that underpin familial melanoma may also be relevant to other cancers. 
Familial clustering of additional cancers has been observed in melanoma families, particularly 
pancreatic cancer linked to CDKN2A mutations, and the evidence for melanoma being part of 
broader cancer syndromes is mounting.1, 4 
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HIGH PENETRANCE GENES 
 
CDKN2A 
 
The CDKN2A gene on chromosome 9p21 consists of four exons that encode two unrelated proteins 
in different reading frames arising from alternatively spliced transcripts. p16 inhibitor of cyclin-
dependent kinase 4 (p16INK4A) is produced from the alpha transcript of exons 1!, 2, and 3, 
whereas p14 alternate reading frame (p14ARF) is produced from the beta transcript of exons 1", 2, 
and 3. The main tumour suppressor activity of p16INK4A is through inhibition of cyclin-dependent 
kinases 4 and 6 (CDK4 and CDK6), thus maintaining retinoblastoma protein (RB) in a hypo-
phosphorylated state to prevent cell cycle S-phase entry.5 p14ARF is a positive regulator of p53, 
and therefore a loss of p14ARF allows for accumulation of DNA damage as cells escape the 
senescence barrier.5 The structure of CDKN2A into two reading frames means that mutations can 
affect either p16INK4A, p14ARF, or both, depending on which exon is affected. Autosomal 
dominant inheritance of germline CDKN2A mutations has been implicated in approximately 20-
40% of familial melanoma, although the mutation frequency varies between different geographic 
regions.5 
 
Geographically-linked founder mutations have been documented, with some occurring as a single 
predominant mutation based on common ancestry. CDKN2A founder mutations have been found in 
Sweden and the Netherlands, namely p.Arg112dup and p16-Leiden respectively, both located in 
exon 2 and originating in northern Europe approximately 2000 years ago.6 Another dominant 
variant has been identified in Iceland, with G89D mutation contributing to the genesis of 
approximately 2% of all invasive cutaneous melanoma in that country.7 In Europe, G101W occurs 
as a founder mutation in France, Italy, and Spain.5 A number of common mutations are shared 
between Australia and the United Kingdom, including M53I, IVS2-105A/G, R24P, and L32P, 
reflecting a shared ancestry from British colonisation of Australia in the late 18th century.5 
Differences in mutation penetrance between regions likely reflect a combination of genetics and 
environment associated factors, where family members are predicted to share the same ultraviolet 
radiation (UVR) exposures as well as a number of other heritable genetic modifiers.1 Several 
independent features have been associated with positive CDKN2A mutation status, including 
multiple primary melanomas, high number of family members with melanoma, Breslow thickness 
>0.4 mm, and early age of melanoma onset.8, 9 Compared with the relatively high penetrance in 
cohorts of familial melanoma, a much lower lifetime risk has been identified for individuals with 
CDKN2A mutation in population-based analysis.10 
 5 
Amongst the high penetrance familial melanoma genes, CDKN2A is unique in that it has also been 
identified as a low penetrance gene conferring increased risk of melanoma in the general 
population. Genome-wide association studies (GWAS) have shown that variants located around the 
CDKN2A locus are associated not only with cutaneous melanoma, but also with naevus count and 
with tanning ability.2, 11-13 Several independent variants are proposed to contribute to complex 
association signals in the CDKN2A region, and the association with melanoma risk is likely to 
involve multiple single nucleotide polymorphisms (SNPs).2 These SNPs include rs869330 and 
rs7023329 within the MTAP gene, and rs1101970 in CDKN2B-AS1 (Figure 1).2, 14 
 
 
 
Figure 1. Recently identified single nucleotide polymorphisms on chromosome 9p21 and 9p22 in 
MTAP, CDKN2A, and CDKN2B-AS1. In MTAP: rs869330 at position 21804617, and rs7023329 at 
position 21816528; in CDKN2A: rs3088440 at position 21968159, and rs3731204 at position 
21984661; in CDKN2B-AS1: rs1011970 at position 22062134.2, 14 Arrows indicate the direction in 
which genes are transcribed. Units next to the chromosome ideogram indicate megabase position of 
each gene from the terminus of the short arm of chromosome 9. Exons (open boxes) of CDKN2A 
are numbered, and dotted lines show how alternative splicing generates the alternate reading frame 
(ARF) and INK4A gene products. 
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The above locus is a naevus associated region, with CDKN2A mutation carriers displaying a higher 
total naevi number and total naevi density compared with non-carriers.15 Phenotypic naevus 
differences have also been observed, with mutation carriers demonstrating significantly more 
clinically atypical naevi (Figure 2).15 An atypical naevus has been defined as having one or more of 
the following clinically observed features: size >5mm in diameter, border or contour irregularity, 
colour asymmetry or multiple colours, and diffusion of pigment. Some CDKN2A coding region 
mutation carriers have a clinical phenotype consistent with atypical naevus syndrome, historically 
also sometimes referred to as dysplastic naevus syndrome, however the variability of phenotypic 
expression means that not all carriers have atypical naevi.15 
 
 
 
Figure 2. Atypical naevi showing the hallmarks of large size, border or contour irregularity, colour 
asymmetry or multiple colours, and diffusion of pigment. (A) many atypical naevi on the back; (B) 
close-up view of centre back naevi seen in A, showing highly irregular contour and colour 
variation; (C) dermoscopy of left naevus marked ‘2’ in (A and B), demonstrating peripheral 
reticular distribution of pigment relatively homogeneously associated with some centrally 
distributed globules and pigment reinforcement. Overall the lesion is relatively symmetrical; (D) 
dermoscopy of right naevus marked ‘1’ in (A and B) showing atypical reticular distribution of 
pigment with asymmetry in the vertical axis. Relative enlargement of pigment network in focal 
areas is more central with some radial streaming. Overall the lesion is relatively homogeneous in 
colour and does not have any blue/white veiling, regression or other hallmarks of melanoma; (E) an 
atypical naevus of large size, asymmetry, irregular pigmentation and contour; (F) close-up view of 
naevus seen in (E and G) dermoscopy of naevus seen in (E and F), showing predominantly reticular 
distribution of pigment with some areas of amorphous pigment. Asymmetry in the vertical axis, 
heterogeneous distribution of pigment and irregular borders. Multiple brown/grey dots centrally and 
symmetrically distributed. No blue/white veil, no regression or other hallmark of melanoma 
(diagnosis to be interpreted in the context of other lesions on the same patient). 
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CDK4 
 
Germline mutations in CDK4 on chromosome 12q14 impact the same pathway as CDKN2A 
mutations, and the oncogenic effects of CDK4 mutations are primarily via the control of cell 
cycling in the G1 phase.16 Two different mutations have been identified, in codon 24 of exon 2, 
leading to substitution of arginine with either histidine or cystine. These R24C and R24H mutations 
lead to CDK4 behaving as a dominant oncoprotein through loss of binding to p16, its negative 
regulator.16 Thus far, a total of 18 families with CDK4 mutations have been identified worldwide. 
The R24C variant has been found in six families, from France, Italy, the United Kingdom, and the 
United States.16 The R24H variant has been found in the other 11 families, comprising three Latvian 
families, two French families, and one family each from Australia, Denmark, Greece, Italy, 
Norway, and the United Kingdom.16-19 In an analysis of 17 families, median age at first melanoma 
diagnosis was 39 years, and the lifetime mutation penetrance based on the available data was 
estimated at 74%.16 The low frequency of CDK4 mutations means that very large population studies 
are required to accurately assess the contribution of CDK4 mutations to the overall burden of 
familial melanoma and the penetrance of cutaneous melanoma in the context of these mutations. 
 
BAP1 
 
Germline inactivating mutations in BRCA1-associated protein-1 (BAP1), a tumour suppressor gene 
on chromosome 3p21, were initially identified in two distinct syndromes. Testa et al (2011) 
identified one as characterised by familial aggregation of mesothelioma and uveal melanoma, and 
Wiesner et al (2011) concurrently described the other as characterised by multiple morphologically 
distinct cutaneous melanocytic neoplasms and uveal melanoma.20, 21 The familial aggregation of 
cancers associated with a proposed BAP1 syndrome has subsequently been expanded to include 
cutaneous melanoma, and additional neoplasms are increasingly being linked to BAP1 germline 
mutations, including meningioma, cholangiocarcinoma, renal cell carcinoma and basal cell 
carcinoma.22-28 The diversity of cancers suggests that the inactivating mutation is variably penetrant 
for different tumour types, and possibly that mutations in BAP1 depend on other unidentified 
genetic modifiers for a cancer phenotype to be expressed. The first recurrent BAP1 mutation has 
recently been reported in three families from two continents, with one family carrying a likely 
independent mutation based on founder haplotype analysis.28 A clustering of uveal and cutaneous 
melanoma in these families, and the presence of only one mesothelioma case, supports the 
hypothesis that specific BAP1 variants predispose to certain subsets of cancers. 28 
 
 8 
A cutaneous phenotypic feature for BAP1 germline mutations has been proposed by the presence of 
multiple 0.2-1.0 cm pink to tan papules and nodules, termed ‘melanocytic BAP1-mutated atypical 
intradermal tumours’ (MBAITs), or alternatively, ‘BAPomas’.21, 29-31 These lesions are similar but 
histopathologically distinct from atypical Spitz tumours, lacking characteristic Spitz naevi features, 
and are also phenotypically distinct from naevi seen in carriers of mutations in other melanoma 
predisposition genes such as CDKN2A (Figure 2 and Figure 3).31 As these lesions typically occur at 
a younger age than other cancers, accurate identification could alert to the possibility of BAP1 
mutation and prompt amplified cancer surveillance. Although the MBAITs associated with BAP1 
mutations were initially reported not to progress to cutaneous melanoma, atypical features of faint 
orange-red pigment, red papule morphology, and halo formation have been described in cutaneous 
melanomas of individuals in BAP1 mutation positive families.23, 24, 32 The features may represent an 
overlap between the phenotype and cutaneous melanoma, either through transformation of an 
existing MBAIT, or de novo melanoma development with a phenotype influenced by the specific 
BAP1 cancer pathway. Of 21 presently reported families affected by BAP1 mutations, 16 families 
had at least one individual affected by cutaneous melanoma, confirming the place of melanoma in 
the BAP1 syndrome.20, 22-25, 27-29, 31-35 BAP1 functional inactivation is also proposed to contribute to 
a small proportion of sporadic cutaneous melanoma, with an absence of BAP1 expression on 
immunohistochemistry staining described in approximately 5% of tumours. 36 Therefore, in the 
context of familial aggregation of cutaneous melanoma, a tumour with somatic loss of 3p and/or the 
loss of BAP1 protein expression may suggest screening for a BAP1 germline mutation is warranted. 
 
 
 
Figure 3. Examples of melanocytic BAP1-mutated atypical intradermal tumours 
(MBAITs)/BAPomas, demonstrating pink to tan papules and nodules, usually symmetrical in shape 
and of fairly uniform colour, which contrasts with the phenotype of atypical naevi (Figure 2), often 
seen in CDKN2A mutation carriers. 
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POT1 
 
Protection of telomeres 1 (POT1) contributes to the six-component protein complex of shelterin, 
which protects telomeres by preventing them from being mistakenly recognised as deleterious DNA 
breaks, regulating telomere region DNA replication, as well as telomerase recruitment and 
activity.37 Two recent studies have identified nine highly penetrant germline mutations in the POT1 
gene, the majority of which affect oligonucleotide/oligosaccharide-binding (OB) fold domains, 
which are essential for the binding of POT1 to telomeric single stranded DNA.37-39  
 
POT1 variants appear to be highly penetrant, with one study of melanoma families from the United 
Kingdom, the Netherlands, and Australia observing that all nine carriers developed melanoma, in 
addition to some individuals developing breast and small cell lung cancer.38 Melanoma associated 
POT1 mutations include a p.Tyr89Cys variant of the N-terminal OB domain in a five-case family, 
and a splice-acceptor variant between exons 17 and 18 in a six-case family.38 Two further OB fold 
domain mutations, p.Gln94Glu and p.Arg273Leu, were each found in a case from different 
families.38 
 
A rare novel missense variant in the OB2 domain, p.Ser270Asn, was detected in all 11 cases and 
obligate carriers from four Italian families, with the same variant also identified in one of two 
affected individuals in a bi-lineal Italian family.39 Although all five families were apparently 
unrelated, the haplotype of the POT1 region was shared by all carriers, suggesting a common 
ancestor approximately ten generations ago as the source of the founder mutation.39 Two further 
POT1 variants, p.Gln623His and p.Arg137His, were identified in another two Italian families.39 In 
both studies, telomeres of POT1 mutation carriers were relatively long, which has previously been 
identified as a risk factor for melanoma.40 
 
ACD/TERF2IP 
 
Recently, mutations in other shelterin complex genes have been found to predispose to melanoma 
(Figure 4). Mutations in the adrenocortical dysplasia protein homolog (ACD) and telomeric repeat 
binding factor 2 interacting protein (TERF2IP) genes were identified in a study of melanoma 
families without known genetic aetiology.38, 39, 41 In a cohort of melanoma families that were wild-
type for known predisposition genes, segregating mutations in ACD were found in four families, 
and another two mutations were identified that did not segregate with all melanoma cases in the 
families.41 A nonsense mutation in one Australian family, p.Q320X, segregated in all four cases 
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available for genotyping, and was associated with early age at diagnosis. Another mutation, 
p.N249S, was identified both in an Australian family and a Danish family, with a shared founder 
haplotype across the ACD locus. In the Australian family, with eight confirmed and four 
unconfirmed cases of cutaneous melanoma, the mutation segregated in all seven cases available for 
testing. Of five confirmed and one unconfirmed case in the Danish family, three affected family 
members were found to be carriers. Both p.Q320X and p.N249S are within the POT1 binding 
domain of ACD, reflecting the key role of the ACD/POT1 sub-unit in mediating the elongation of 
telomeres.41 
 
TERF2IP is important in the negative regulation of telomere length, by repressing homology-
directed repair. A nonsense mutation and three novel missense variants have been identified. The 
p.Q191R was associated with onset of melanoma at 15 and 24 years, and is predicted to disrupt the 
binding site for TERF2.41 This loss is proposed to prevent TERF2IP contributing to the shelterin 
complex. A case-control analysis of the ACD and TERF2IP mutations in sporadic melanoma cases 
did not identify any carriers, indicating that rare mutations are likely to be significant only in a 
familial context.41 
 
TERT  
 
Progressive shortening of telomeres with each cell division is a characteristic of normal aging, and 
may be hastened by exposure to harmful environmental risks such as UVR. Maintenance of 
telomere length is a function of telomerase, and altered telomerase regulation contributes to the 
limitless replicative potential of cancer cells. Telomerase reverse transcriptase (TERT) encodes a 
catalytic subunit of telomerase, and somatic TERT promoter mutations have been identified in a 
variety of cancers, including melanoma.42 TERT has also recently been implicated in familial 
melanoma following high-throughput sequencing of four affected and four non-affected individuals 
in a 14-case German family.43 After the region was first identified by multi-point linkage analysis, 
sequencing of all genes in the region revealed several novel variants, including a T>G variant in the 
TERT promoter.43 This germline mutation was found in all four affected individuals, as well as one 
unaffected member who was only 36 years old and had multiple naevi.43 Two affected individuals 
developed melanoma at age 20 and age 30, in addition to other cancers, suggesting that this 
mutation is a rare but highly penetrant melanoma risk mutation. Screening of 168 cell lines from 
sporadic metastatic melanoma did not find other occurrences of this novel germline variant, 
although somatic recurrent UVR-signature mutations elsewhere in the TERT promoter were present 
in 125 of the cell lines.43 
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Figure 4. High, medium and low penetrance genes and their chromosome band locations. Black 
text denotes high penetrance genes; blue text denotes medium penetrance genes; red text denotes 
low penetrance genes. 
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MEDIUM PENETRANCE GENES 
 
The relatively low frequency of high penetrance mutations suggests that a multitude of alternative 
germline mutations could help explain melanoma predisposition. Medium and low penetrance 
alleles are more prevalent in the general population, but singularly, they are unlikely to be enough 
to drive oncogenesis.44 However, the complex interplay of several of these alleles may combine to 
raise the level of personal melanoma risk above a critical threshold. In this regard, a component of 
polygenic heritability has been demonstrated to underlie all sporadic cancers.44 To date, three 
medium penetrance genes (i.e. those with variants that have odds ratios of disease association of 
between 2 and 5) predisposing to melanoma have been identified. Interestingly, all three are 
involved in natural variation in pigmentation (summarised below). 
 
MC1R 
 
The melanocortin 1 receptor gene (MC1R) encodes the G-protein coupled receptor MC1R, which 
binds !-melanocyte stimulating hormone (!-MSH).45 Binding of the ligand normally activates 
adenylate cyclase, which then increases intracellular levels of cyclic adenosine monophosphate 
(cAMP). Raised cAMP triggers a subsequent cascade via downstream microphthalmia-associated 
transcription factor (MITF) and tyrosinase to stimulate melanocyte proliferation, dendricity, and 
eumelanin pigment synthesis (Figure 5).45 The increase of photoprotective black/brown eumelanin 
pigments decreases the relative amount of red/yellow pheomelanins, which are poorly protective 
against UVR. The type and quantity of pigment determines phenotypic expression of skin and hair 
colour, as well as skin sensitivity to UVR and tanning response. A number of variant MC1R alleles 
associated with reduced cell surface receptor expression have been identified. This situation reduces 
binding of !-MSH, and subsequently lower cAMP levels result in less eumelanin and a greater 
proportion of pheomelanins.45-47 
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Figure 5. MC1R and the pigment synthesis pathway. Binding of !-melanocyte stimulating 
hormone (!-MSH) to its cognate receptor MC1R on the surface of a melanocyte triggers cyclic 
AMP (cAMP) production via adenylate cyclase (AC). This activates the CREB and MITF 
transcription factors, causing an increase in expression of several components of the melanin 
synthesis pathway, and leads to a switch in pigment production from pheomelanin to eumelanin in 
melanosomes. 
 
 
MC1R is highly polymorphic and a link has been established between particular alleles and a red 
hair colour (RHC) phenotype. Variants most strongly associated with the RHC phenotype are 
termed R alleles, and the consequently reduced or non-functional cell surface receptors and 
increased pheomelanin causes the phenotypic traits of red hair colour, fair skin, freckling, and 
inability to tan.45 Other MC1R variants that are more weakly associated with RHC and have less 
penetrant impact on the cell receptors are designated r alleles. RHC associated MC1R variants are 
typically inherited in an autosomal recessive pattern.45 Variants may be inherited in a heterozygous 
+/R or +/r pattern, or a homozygous R/R or r/r state. Although red hair colour is generally a 
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recessive trait, increases in the percentage of individuals with fair skin, blonde hair, and red hair 
reflect in vitro studies of a dominant negative effect of MC1R variant receptors on co-inherited 
wild-type alleles.45 Variants associated with melanoma include the R alleles D84E, R142H, R151C, 
R160W, and D294H, (with odds ratios of 1.85-2.90) and the r alleles V60L, V92M, I155T, R163Q, 
and T314T (with odds ratios of 1.37-2.61).48, 49 A French case-control study recently identified 69 
rare MC1R polymorphisms, including 25 novel melanoma predisposition variants.48 Just over half 
of the identified alleles were predicted to have a functional impact (D variants).48 Of the novel 
alleles, 14 D variants were exceedingly rare, each associated with only a single case in the 
melanoma cohort. Several others were identified in the control group.48 
 
A pooled analysis with a large sample size from 17 case-control studies found that individuals 
carrying a single MC1R variant had an almost 40% increased risk of melanoma compared to 
homozygous wild-type controls, and that the risk attributable to any MC1R variant was 28%.49 For 
carriers of two or more MC1R variant alleles, the risk of cutaneous melanoma was more than 
double the risk found for wild-type controls.49 Interestingly, for individuals with the RHC 
phenotype, presence of MC1R variants alone was insufficient to independently predict melanoma 
risk.49 This could possibly reflect the significant role of environment and UVR in modulating risk 
for RHC variant carriers. 
 
The analysis also revealed an association between MC1R variants and melanoma for Caucasian 
patients with darkly-pigmented skin.49 Notably, the MC1R variant/melanoma association has been 
reported as stronger for photoprotective phenotypes.49, 50 This may reflect the putative role of MC1R 
in non-pigment pathways, including activation of nucleotide excision repair and other DNA repair 
mechanisms in response to UVR damage.51-53 For variant alleles, a compromised UVR response has 
been attributed to a diminished !-MSH mediated oxidative stress response and reduced effects on 
target DNA damage response genes.53 This link to DNA repair helps explain the role of MC1R in 
melanoma susceptibility, suggesting that variant alleles may utilise either pigment or non-pigment 
pathways to cause melanoma. The non-pigment pathways are particularly relevant for variants that 
are associated with melanoma but not with the RHC phenotype.49 
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MITF 
 
The MITF gene encodes the transcription factor MITF, and is a key regulator of pigment cells, 
including the development and differentiation of melanocytes. A recently identified recurrent 
germline mutation, MITF p.E318K, is responsible for the substitution of glumatic acid at position 
318 with lysine.54, 55 The lysine residue at the site changes the binding affinity for a small-ubiquitin-
like modifier (SUMO) protein, and subsequently decreases SUMOylation.54, 55 SUMO directed 
post-translational modification typically impacts transcriptional regulators to inhibit transcription, 
and thus reduced SUMOylation effectively removes the brakes from MITF action on downstream 
targets.56 Comparison of expression profiles for MITF regulated targets identified 37 genes, with 17 
showing modest differences in expression between wild-type and p.E318K isoforms.55 This 
difference may indicate that variant MITF mutations have particular transcriptional affinity for 
specific sets of target genes. Although the precise molecular mechanisms have yet to be fully 
elucidated, it is apparent that MITF p.E318K acts as a gain of function mutation predisposing to 
familial melanoma. Carriers of the p.E318K variant have been identified as having a significantly 
higher risk of developing melanoma (odds ratios of 2.09-2.19), and the p.E318K mutation has been 
shown to co-segregate with melanoma in multiple families.54, 55 Co-segregation was observed in 
some but not all family members, implying that it is a medium-penetrance melanoma variant, 
similar to MC1R.55 From population analysis of controls, few mutations were detected, therefore 
denoting MITF p.E318K as a rare population variant.55, 57, 58 The p.E318K mutation has also been 
linked with a particular phenotype, comprising non-blue eye colour, increased number of naevi, and 
multiple primary melanomas.54, 55, 57, 58  
 
SLC45A2 
 
In contrast to MC1R and MITF, solute carrier family 45, member 2 (SLC45A2) variants are 
associated with darker skin colour, and appear strongly protective against melanoma. The gene 
product functions as a membrane-associated transporter protein, and is thought to influence 
pigmentation via the processing and trafficking of melanosomal proteins such as tyrosinase.59, 60 
The ancestral variant 374L of rs16891982 has been associated with olive and dark skin, and confers 
a protective effect against melanoma, even for individuals with a fair phenotype (odds ratios of 
2.37-5.50).59, 61, 62 This variant is more common in individuals from Southern Europe and the 
Mediterranean region, and there is a decreasing gradient of allele frequency from the south to the 
north of Europe.60, 63 
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LOW PENETRANCE GENES 
 
In addition to two of the known medium penetrance genes MC1R and SLC45A2, 18 other low 
penetrance risk loci have been associated with melanoma through GWAS (Table 1).64 Agouti 
signalling protein (ASIP), tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1), and 
oculocutaneous albinism type II (OCA2) are involved in pigmentation.2, 60, 61, 65 ASIP encodes for an 
antagonist of !-MSH, which competitively binds to MC1R, thereby preventing MC1R-mediated 
stimulation of eumelanin synthesis (Figure 5). ASIP has been variably associated with melanoma.2 
Similar to MC1R RHC variants, melanoma-associated ASIP SNPs have been linked to red hair and 
skin freckling.66 TYR impacts eye colour and tanning response, where activity of the enzyme 
tyrosinase influences the ratio of eumelanin to pheomelanin, and thus TYR alterations can contribute 
to a fair skin phenotype (Figure 5).66 TYR SNPs associated with blue eye colour and skin sun 
sensitivity have been significantly associated with melanoma, as have SNPs in TYRP1.2, 66 TYRP1 
stabilises the protein encoded by TYR, and therefore mutations in this gene can also affect tanning 
response.66 Further to known phenotypic associations with melanoma, increased risk has been 
reported for pigment related SNPs in the HERC2/OCA2 region on chromosome 15q13.1.67 The two 
SNPs most significantly associated with melanoma risk are rs1129038 and rs12913832, the latter 
being a key determinant of human blue-brown eye colour.67, 68 PLA2G6 is associated with both 
pigmentation and naevi, while CASP8, TERT, AGR3, MTAP/CDKN2A, and FTO are associated 
with variation in naevus density.14, 61, 63, 65-67, 69-78 In addition to its role in naevus count, TERT is 
also associated with telomere length, as is OBFC1.73 Two loci (PARP1, ATM) are associated with 
DNA repair, and two others are linked to methylthiolation of tRNA and regulation of cell cycle 
progression (CDKAL1 and CCND1 respectively).65, 73, 79, 80 Four other loci: ARNT/SETDB1, 
CYP1B1, MX2, and TMEM38B/RAD23B, are associated with melanoma but via uncertain 
mechanisms.65, 73, 79 
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Table 1   Melanoma loci identified through GWAS 
Gene Chromosome 
band 
Regional 
peak 
OR Pigmentation Naevi Refs 
ARNT, 
SETDB1 1q21 rs12410869 0.88 No No 79 
PARP1 1q42.12 rs1858550 0.87 No No 79, 80 
CYP1B1 2p22.2 rs6750047 0.92 No No 73 
CASP8 2q33.1 rs7582362 0.89 No Weak/Trend 65 
TERT 5p15.33 rs380286 1.16 No Yes 65, 70, 77 
SLC45A2 5p13.3-13.2 rs250417 2.44 Yes, strong No 
61, 63, 65, 
70, 72 
CDKAL1 6p22.3 rs6914598 1.11 No No 73 
AGR3 7p21.1 rs1636744 1.11 No Weak/Trend 73 
MTAP/ 
CDKN2A 9p21.3 rs7852450 0.81 No Weak/Trend 
14, 65, 70, 
76 
intergenic 
(TMEM38B) 9q31.2 rs10739221 0.89 No No 73 
OBFC1 10q24.33 rs2995264 0.87 No No 73 
CCND1 11q13.3 rs498136 0.89 No No 65 
TYR 11q14.3 rs1393350 1.22 Yes, strong No 
14, 66, 69, 
70 
ATM 11q22.3 rs73008229 0.83 No No 65 
OCA2/ 
HERC2 15q12-13.1 rs4778138 0.84 Yes, strong No 
63, 67, 
71-73 
FTO 16q12.2 rs12596638 1.15 No Yes 78 
MC1R 16q24.3 rs75570604 1.82 Yes, strong No 14, 68, 70 
ASIP 20q11.22 rs6059655 1.42 Yes, strong No 
14, 66, 69, 
70, 74, 75 
MX2 21q22.3 rs408825 1.15 No No 65 
PLA2G6 22q13.1 rs2092180 0.89 Yes Yes 
14, 61, 65, 
76 
OR: odds ratio 
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GENETIC MODIFIERS AND INTERACTIONS 
 
Overall risk in familial melanoma is modified by the pooled contribution of many factors, including 
other genes, phenotypic characteristics, and the environment. The addition of modifiers or 
interactions can influence the penetrance of a certain allele, and contribute to increased, or 
decreased, melanoma susceptibility. 
 
Gene-gene 
 
Epistasis is a gene-gene interaction, where the effect of a particular gene depends on the presence of 
another modifier gene. Epistasis can also be linked to multiple genes, where a certain genetic 
background may be essential for subsequent gene expression.81 A number of epistatic mutations 
likely contribute to the polygenic inheritance of melanoma. 
 
Further to its contribution as an independent risk gene for melanoma, MC1R variants act as genetic 
modifiers by increasing the penetrance of CDKN2A mutations. A recent meta-analysis showed that 
melanoma risk doubled for patients with mutations in both CDKN2A and MC1R compared to 
mutated CDKN2A alone, and that carriers of multiple MC1R variants were even more likely to 
develop melanoma.3 For potential interactions of MC1R with other genes located near CDKN2A, all 
ten recently identified candidate polymorphisms on chromosome 9p21 did not show any significant 
association on interaction analysis.11  
 
Telomere length has been also investigated in relation to CDKN2A status, following previous 
associations between cutaneous melanoma and longer telomeres. In contrast to non-carriers, the 
study failed to show a link between telomere length and melanoma for carriers of CDKN2A 
mutations, either suggesting a divergent melanoma pathway in these individuals, or more likely, 
insufficient power to detect an association.40 
 
Interaction between the MITF p.E318K allele and MC1R RHC variants has been variably reported, 
and there does not appear to be an interaction in the majority of patients.58, 82 However, one patient 
in an Australian cohort with a p.E318K allele and MC1R homozygous R/R genotype developed 
three amelanotic melanomas, suggesting a genetic interaction as the source of this phenotype.58 An 
analysis of 33 candidate polymorphisms in several pigmentation genes and the vitamin D receptor 
(VDR) gene identified significant epistatic effects between MC1R and TYR, and SLC45A2 and 
VDR, among others.12 
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MC1R has been proposed to also interact with somatic BRAF p.V600E mutations to drive 
melanomagenesis, likely by allowing cells to bypass senescence.83 In vivo studies have 
demonstrated that the simultaneous expression of BRAF p.V600E and MC1R depletion results in 
greater melanocyte growth and tumour formation compared to either factor alone.83 
 
Gene-phenotype 
 
Pigmentation traits with less melanin are linked to melanoma via reduced protection against UVR. 
Phenotypic risk factors for melanoma in the general population include blue or green eyes, fair or 
red hair, fair skin with increased sun sensitivity and an inability to tan, high numbers of naevi, and 
atypical naevi. Several genetic variants predisposing to pigment and naevus phenotypes have been 
identified in the general population, which in turn have been implicated in predisposition to 
melanoma.45 In addition to the effect on DNA repair, the variant MC1R-mediated RHC phenotype 
of red hair, pale skin, and an inability to tan confers melanoma susceptibility by increased potential 
for sunburn and UVR damage.45 The medium penetrance risk gene MITF has been associated with 
the phenotypic characteristic of high naevus count.55, 58 In an Australian study, carriers displayed 
significantly higher counts of naevi greater than 5 mm, but without distinct dermoscopic naevus 
signature patterns.58 For carriers of the p.E318K mutation, there was an association with non-blue 
eye colour but no association with other known phenotypic characteristics, including skin colour, 
hair colour, and freckling.55 
 
Gene-environment 
 
The most significant independent environmental risk factor for melanoma is UVR exposure, and a 
potential interaction between geographic location and CDKN2A penetrance has been observed. A 
large international study of families from three continents found significant variation in mutation 
penetrance depending on geographical location, likely correlating with associated UVR exposure.1 
By age 50, mutation penetrance reached 0.13, 0.50, and 0.32 in Europe, the United States, and 
Australia, respectively. By age 80, it was 0.58 in Europe, 0.76 in the United States, and a staggering 
0.91 in Australia.1 Although these penetrance rates appear to correspond with latitude and hence 
UVR exposure, it is possible that varying penetrance of different region specific CDKN2A variants 
or co-inheritance of other genetic modifiers could contribute to the differences. Tobacco smoke has 
been linked to increased penetrance of CDKN2A for pancreatic, upper gastrointestinal, and 
respiratory cancers, and it is hypothesized that it may also affect CDKN2A penetrance for 
melanoma.4 
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FAMILIAL MELANOMA MUTATIONS AND RISK OF OTHER CANCERS 
 
Some familial cutaneous melanoma predisposition genes have also been linked to risk of other 
tumour types, where the incidence of specific cancers occurs within melanoma families at rates 
greater than expected by chance (Table 2). 
 
Table 2   Melanoma predisposition genes and associations with other cancers 
Gene Chromosome 
band 
Modifiers Associated non-
cutaneous 
melanoma cancers 
Possibly associated cancers* Refs 
CDKN2A 9p21 MC1R, 
UVR, 
possibly 
tobacco 
smoke 
Pancreas ENT (tongue, oral cavity, 
pharynx, larynx), upper digestive 
(oesophagus, stomach), brain, 
breast, cervix, gall bladder, 
thyroid, leukaemia, liver, lung, 
lymphoma, renal 
5, 6, 
85, 
86 
CDK4 12q14 - - Breast, cervix, colorectal, lung, 
lymphoma, pancreas, stomach, 
uterine 
17-
20 
BAP1 3p21.1 - RCC, uveal 
melanoma, 
mesothelioma, 
BCC, 
cholangiocarcinoma 
Bone, bladder, breast, colorectal, 
lung adenocarcinoma, 
meningioma, neuroendocrine, 
ovarian, paraganglioma, 
stomach, thyroid 
21-
36 
MITF 3p14.2 Possibly 
MC1R 
RCC, pancreas Bladder, brain (glioblastoma), 
breast, colorectal, endometrial, 
leukaemia, lung, lymphoma, 
myeloma, prostate, stomach 
55, 
56, 
58 
TERT 5p15.33 - - Bladder, breast, endometrial, 
lung, ovarian, renal 
43, 
44 
POT1 7q31.33 - Glioma Brain, breast, CLL, endometrial, 
leukaemia, thyroid, SCLC 
39, 
40, 
90, 
91 
ACD 16q22.1 - - Breast, colorectal, leukaemia, 
lung, lymphoma 
42 
TERF2IP 16q23.1 - - Breast, cervix, meningioma, 
ovarian 
42 
BCC: basal cell carcinoma; CLL: chronic lymphocytic leukaemia; RCC: renal cell carcinoma; SCLC: 
small cell lung cancer; UVR: ultraviolet radiation 
* Possibly associated cancers include those documented in pedigrees of affected individuals and their 
non-wild type untested family members 
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The most extensively documented association is between CDKN2A and pancreatic cancer, although 
associations have been noted for a range of other cancers.4, 5, 84, 85 A study of carriers of the Swedish 
p.Arg112dup CDKN2A founder mutation found significantly increased risk of pancreatic cancer, 
upper digestive (oral cavity, tongue, pharynx, larynx, oesophagus, stomach, liver, gall bladder) 
cancers, and respiratory (bronchi and lung) cancers.4 , At age 80 years, 53% of carriers were 
reported to have at least one of these specific cancers.4 Interestingly, the risk of cancer was 
significantly higher in individuals who had ever smoked, compared with carriers who had never-
smoked.4 Upper gastrointestinal and respiratory tissues are particularly sensitive to carcinogens, and 
exposure to tobacco smoke and other environmental carcinogens may increase the penetrance of 
CDKN2A in these cancers in a similar manner to UVR and melanoma. An international study 
reported an increased risk of all non-melanoma cancers in first degree relatives of CDKN2A 
mutation carriers.84 For mutation carriers, the lifetime risk of any cancer other than melanoma was 
estimated at 59% by age 85.84 
 
Further to CDKN2A variants and melanoma risk, the 9p21 locus has been linked to a variety of 
other cancers. An analysis of eight different GWAS identified several significant SNPs in this 
region, including some variants associated with multiple cancers.86 Of particular note may be the 
CDKN2A intronic rs3731239 SNP, which was associated with oesophageal squamous cell cancer, 
gastric cancer, and breast cancer.86 Although these results to do not directly relate to specific 
melanoma risk SNPs, it is interesting to consider the potential impact of this region to cancer 
susceptibility more generally, and as a potential site for other novel cancer predisposition variants. 
 
An association with multiple cancers has also been indicated for POT1.38, 39 Other cancer types 
include breast cancer, small cell lung cancer, endometrial cancer, and brain tumours, which have 
been observed in POT1 mutation carriers and their untested family members. There may also be a 
link with chronic lymphocytic leukaemia (CLL), which has somatic mutations in POT1 at relatively 
high frequency, the majority of which affect the OB folds, a finding that is in keeping with 
alterations detected in the recent melanoma studies.38, 39, 87, 88 One POT1 mutation carrier had a 
history of both melanoma and CLL, and it is possible that a variant exists that could affect a portion 
of the OB fold domain that is relevant to the development of both melanoma and CLL.38 
 
Additionally, POT1 has recently been implicated in the development of glioma.89 Three novel 
protein-changing variants have been described, each found in one family with a high case density of 
glioma. In one family with six carriers and one obligate carrier of p.G95C, three individuals 
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developed glioma at young ages.89 Of six carriers in a family with a p.E450X mutation, two were 
affected by glioma.89  
 
Glioma has previously been tentatively associated with melanoma following the observation of 
more melanoma cases than expected in glioma families.90 Although the underlying basis for 
susceptibility is uncertain, analysis of potential glioma susceptibility loci by GWAS has identified 
variants in chromosome 9p21 near CDKN2A and CDKN2B.91, 92 The glioma candidates are not in 
the same linkage disequilibrium block as the CDKN2A melanoma gene, but it suggests the 
possibility that this region may account for shared predisposition to both cancers.  
 
More cancers than expected has also been found in families carrying ACD and TERF2IP mutations, 
which like POT1, affect the shelterin complex. Although the numbers are too few to be statistically 
significant, additional cancers in carriers with melanoma include lung, breast, bowel, and 
haematological malignancies, suggesting a possible ACD/TERF2IP associated spectrum of 
cancers.41 
 
Somatic TERT promoter mutations have been found in a wide range of different cancer types, and 
the occurrence of multiple additional cancers in individuals affected by a novel germline promoter 
mutation suggests that these other cancers could be due to dysregulation of TERT.42, 43 One 
individual was diagnosed with endometrial cancer at age 27 and melanoma at age 30. A second 
affected family member developed melanoma at age 20, then subsequently had ovarian cancer, 
renal cell carcinoma (RCC), bladder cancer, mammary carcinoma, and bronchial carcinoma before 
her death at age 50.43 It has been suggested that the nucleotide sequence change in the germline 
variant creates a binding motif similar to one already used by the ternary complex factor Elk1, 
which has been demonstrated as a transcriptional regulator in breast, cervical, and endometrial 
cancer.43, 93-95 Although a tenuous link, this could help explain gender related differences as well as 
the presence of endometrial, ovarian, and breast cancer. 
 
A bidirectional association has been established between melanoma and RCC for sporadic cases, 
and a number of familial melanoma studies have also noted an over-representation of this cancer.96 
Both RCC and pancreatic cancer have been linked to the p.E318K mutation in MITF, and a 
potential connection between melanoma and lymphoma has been noted.54, 55, 57 Mutation p.E318K 
upregulates hypoxia inducible factor, which has been identified as the downstream target of other 
known RCC predisposition genes.54 BAP1 has also recently been associated with the development 
of RCC. In an analysis of 60 French families with BAP1-reminiscent cancer clustering, RCC-
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affected individuals were identified in six out of 11 families with germline BAP1 mutations.26 A 
novel variant has been detected in one American family with multiple cases of RCC but no other 
cancers, suggesting that germline BAP1 mutations may rarely predispose solely to RCC.97  
 
The high density of cancer in families affected by germline BAP1 mutations suggests that this gene 
is a critical regulator of oncogenesis for the tumours identified.30 The numerous functional domains 
of the BAP1 protein present a range of potential sites for mutation. Therefore a number of germline 
variants may exist, each possibly contributing to a different collection of cancers. Further to the 
heterogeneity of BAP1 mutations, it is likely that modifier genes and environmental factors also 
impact the cancer phenotype in BAP1 families. A BAP1 cancer cluster comprised of 
cutaneous/ocular melanoma, atypical melanocytic proliferations, and other internal neoplasms such 
as mesothelioma (COMMON) has been proposed as a particular syndrome.23 However, further 
studies have implicated a range of other cancers as part of a possible BAP1 spectrum. In addition to 
RCC, possibly associated neoplasms include lung adenocarcinoma, meningioma, paraganglioma, 
breast cancer, neuroendrocrine tumours, gastric cancer, and basal cell carcinoma.22, 24, 25, 27, 28 These 
findings hint at the prospect of many other BAP1 associated cancers as more families are identified. 
 
FAMILIAL CANCER SYNDROMES AND MELANOMA RISK 
 
A number of other rare autosomal familial cancer syndromes have been described, characterised by 
the occurrence of multiple cancers including melanoma. These include Li-Fraumeni syndrome, 
xeroderma pigmentosum, Werner syndrome, and familial breast cancer. Li-Fraumeni syndrome is 
linked to TP53, and germline mutations are associated with breast cancer, bone and soft tissue 
sarcomas, brain tumours, and adrenocortical carcinomas.98, 99 The inclusion of melanoma in the 
syndrome has been controversial, however a handful of melanoma cases have been reported, 
including one patient with a germline TP53 mutation who presented with multiple primary 
cutaneous melanomas.100 In contrast, xeroderma pigmentosum is an autosomal recessive condition 
caused by mutations in one of eight nucleotide excision repair genes, and the DNA repair function 
they encode is crucial to the cellular response to UVR-induced DNA damage.101 Coupled with UVR 
damage, this failure in DNA repair predisposes to increased sun sensitivity and skin cancers. A 
2,000 and 10,000 fold increase in melanoma and non-melanoma skin cancer, respectively, has been 
reported, as well as an increase in neural system cancers.101 Werner syndrome is also autosomal 
recessive, and loss of function mutations in the WRN gene lead to premature aging and multiple 
cancer susceptibilities, with the spectrum comprising thyroid cancer, melanoma, meningioma, 
sarcomas, and leukaemia.102 Analysis of tumours other than breast cancer in carriers of BRCA1 or 
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BRCA2 mutations has shown that BRCA2 defects are associated with 2.6-fold and 99.4-fold 
increased risks of cutaneous and uveal melanoma respectively, but there is no increase in melanoma 
risk associated with BRCA1 mutation.103, 104   
 
CLINICAL IMPLICATIONS AND FUTURE PRACTICE 
 
The identification of cancer predisposition genes by genetic testing is typically only recommended 
when the results influence clinical decisions and treatment can be implemented to prevent or 
improve clinical outcomes.105 Genetic testing in melanoma is therefore controversial, due to the 
relatively low frequency of high penetrance mutations and the contribution of multiple additional 
factors that modulate melanoma risk. Despite this, heightened surveillance and more regular skin 
checks could be a useful outcome for a patient with a known susceptibility. 
 
One of the main benefits encountered from genetic testing is that it may prompt useful discussions 
about melanoma risk, early detection, and prevention with multiple family members. The impact of 
melanoma risk discussion on the effect on future sun safety behaviours has been demonstrated in a 
group of family members identified for CDKN2A testing.106 Two years following genetic testing, 
individuals sustained improvements in daily sun protection and fewer sunburns, with no diminution 
after a negative test result.106 Although this study is subjective, it highlights the potential positive 
impact of increasing awareness and education. Counselling may therefore form an opportunistic 
intervention to motivate preventative behaviours and minimise UVR exposure risk. 
 
With time, it is anticipated that the data pool of presently known variants will expand, which will be 
particularly important for analysis of rare variants in a wider population. For families with a high 
cancer burden but no carriers of previously identified predisposition genes, next-generation 
sequencing will be key to identifying potential novel high penetrance variants and narrow the 
present knowledge gap. If future studies indicate clinical utility for genetic testing, it is likely that 
only high penetrance predisposition genes would be prioritised for gene panels dedicated to 
melanoma risk evaluation. Although the epistatic effect of MC1R variants on CDKN2A penetration 
has been noted, it is less likely that low or medium penetrance risk genes would be used as routine 
screening tests due to the uncertainty of predicting the clinical outcome of disease development.3 
 
Progressing from attribution of melanoma risk, future practice in familial melanoma may involve 
novel susceptibility genes as a basis for development of early detection strategies. The possibility of 
combining clinical and genetic information for prognostic estimates has been proposed, where a 
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novel logistic regression model of two significant SNPs, histological tumour type, and stage at 
diagnosis had an improved discrimination of 3-year melanoma recurrence compared to histology 
and stage alone.107 A recently published study analysed 2,339 SNPs in 14 autosomal genes of the 
Fanconi anaemia pathway, which is involved in the crosslink repair of DNA. Four SNPs were 
significantly associated with reduced overall survival and melanoma-specific survival, and 
combination of these factors with tumour stage and Breslow thickness further refined 5-year 
predictive ability.108 
 
Although the potential for targeted treatments directed at germline mutations seems unlikely, it may 
be plausible in the future, particularly for high penetrance genetic variants with both germline and 
sporadic manifestations. 
 
CONCLUSION 
 
Overall, the landscape of melanoma risk genes is becoming gradually less mysterious, with the 
addition of BAP1, POT1, ACD, TERF2IP, and TERT to the known high penetrance melanoma risk 
genes CDKN2A and CDK4. Ongoing studies of recently identified pigmentation genes in a wider 
population will be highly significant in both their independent risk and the additional risk conferred 
by gene-gene and gene-phenotype interactions. Novel candidate genes are promising, however there 
likely still remains a great many to be elucidated. The contribution of melanoma risk genes to other 
cancers is particularly important for families with observed cancer clustering, where novel genes 
may also predispose to other cancers. In the future, it is plausible that melanoma risk genes could be 
used for genetic counseling of melanoma as well as the other cancers they influence. The most 
important outcome of familial melanoma research will be in clinical application, and even without 
genetic testing, awareness of the hereditary component of melanoma is likely to improve health 
promotion and advocacy as part of holistic patient care. Future research will continue to validate 
known risk genes in wider populations, and will also aim to discover novel predisposition genes for 
the large percentage of families with a high case density but no identified presently known genes. 
Although routine genetic testing is currently not recommended due to the complex polygenic 
interplay that influences the clinical picture of melanoma, the potential for predisposition genes to 
be utilised as screening tools, for prognostic information, and as targets for treatment may be 
important in future practice. 
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Chapter 3 
Increased incidence of bladder cancer, lymphoid leukaemia, and myeloma in a cohort of 
Queensland melanoma families 
 
INTRODUCTION 
   
In contrast to ‘sporadic’ cancer, occurring in the absence of family history or known risk genotype, 
the clustering of multiple cancers has been observed in some families. Familial risk has been 
proposed as a shared feature of many cancers, particularly for those diagnosed at a younger age and 
with multiple affected family members.1-4 The degree to which certain cancers aggregate in families 
has been difficult to define, due to the heterogeneity of possible high penetrance germline 
mutations, low to moderate risk polymorphisms, genetic and environmental modifiers, and 
individual lifestyle factors.1, 4, 5 However, it appears that risk of some cancers is more heritable than 
others.5, 6 
 
A positive family history is associated with increased risk of melanoma, and although familial 
melanoma prevalence varies by geographic region, approximately 10% of Australian melanoma 
cases have an affected relative.7, 9 The cumulative risk of melanoma in first degree relatives (FDRs) 
of cases has been estimated at 6-7% by the age of 80 years, with this risk rising to 10% if the 
relative with melanoma was diagnosed before age 50.10 
 
The familial melanoma susceptibility gene CDKN2A is associated with an increased risk of cancers 
other than melanoma, particularly pancreatic and digestive tract cancers.11-14 Other high-penetrance 
melanoma predisposition genes have also been linked to additional non-melanoma cancers, 
including a cancer syndrome comprising cutaneous melanoma, uveal melanoma, and mesothelioma 
associated with BAP1 mutations; renal cell carcinoma with MITF and BAP1; and glioma with 
POT1.15-25 
 
In some families affected by melanoma, additional ‘over-represented’ cancers continue to be 
observed. For both melanoma and other cancers, rare high penetrance loci cannot entirely explain 
observed familial rates, and it is likely that ‘familial’ cancer is influenced by the contribution of 
multiple low risk genes and modifiers inherited by susceptible individuals. 
 
The combination of individual risk alleles may also be important, depending on whether the effects 
are additive or epistatic, and thus the number of inherited variants required for oncogenesis. 
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Differences in populations with strong founder effects, different patterns of low-risk polymorphism 
inheritance, and specific environmental exposures, may result in different clusters of melanoma-
associated cancer types between geographic regions.12 
 
At a population level, a unique underlying predisposition for cancer is likely conferred by the 
combined effects of many low risk loci and exposures, and it is possible that specific cancer types 
share similar combinations of polymorphisms that increase overall risk. 
 
To investigate population level cancer risk for ‘melanoma’ families, the present study seeks to 
assess the risk of cancers other than melanoma in a cohort of families with at least two first-degree 
relatives affected by melanoma, not selected for specific genetic mutations. 
 
MATERIALS AND METHODS 
 
Study inclusion 
 
The study cohort comprises 178 families originally ascertained between 1982 and 1990 as part of 
the Queensland Familial Melanoma Project (QFMP), designated as ‘intermediate risk’ due to 
confirmed cases of melanoma in two first-degree relatives.7 Melanoma was defined as melanoma in 
situ or invasive melanoma. Cases of lentigo maligna and Hutchinson’s melanotic freckle were 
excluded. Of the 415 families in the ‘intermediate risk’ group, these 178 families had not had 
further contact since a follow up study (The Queensland Study of Melanoma: environmental and 
genetic associations (Q-MEGA)) was completed between 2002 and 2005, when one or more 
individuals in each family answered a structured telephone interview relating to personal and family 
cancer information.26 Melanoma cases and their FDRs were considered eligible for the current 
study if they had given written consent or had verified death information. First-degree relatives of 
all confirmed melanoma cases in each family were included, regardless of which individual was the 
proband.  
 
For bilineal families, both family lines were considered, to account for possible polygenic 
inheritance. Individuals with confirmed melanoma who married into a ‘melanoma’ family were 
only considered if they had at least one child who had given written consent or had available death 
information. Individuals without a genetic link to any melanoma case were excluded (i.e. related 
only by marriage, adoption), as were all individuals who were not alive at any point during the 
study period regardless of melanoma status (for reason see below).  
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 Study period 
 
The study period (33 years) commenced in 1982, when it first became mandatory to notify all 
cancers in Queensland to the Queensland Cancer Registry (QCR), and concluded at the end of 
2014. 
  
Cancer verification 
 
Information on cancer diagnoses were obtained and verified from the following sources: 
histopathology from the QCR or any other source; National Death Index (NDI); written 
confirmation from a doctor or medical professional; genetic clinic counselling information; and 
original medical records or cancer information sighted and transcribed by a research nurse. In the 
absence of any other confirmation, a self-reported melanoma excision scar of greater than 5 cm (as 
documented on a historical QFMP questionnaire) was considered acceptable. Any cancer reported 
by an individual or relative that was not supported by any of the above verification criteria was 
excluded. 
  
Cancer type 
 
Cancers were counted only for primary events, not for metastases, unless metastatic disease was the 
first cancer diagnosed. In the case of metastatic disease, events were counted for the histological 
subtype and not the organ with metastatic cancer. In this way, an individual with metastatic 
melanoma to the brain would only be counted for melanoma, not brain cancer. Different cancers of 
the same organ/type in a single individual were counted as separate events only if they were 
primary cancers and were histopathologically distinct. Cancers not reportable to the QCR, such as 
basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the skin, were excluded. 
 
Events were only counted for invasive cancers, in line with the cancer statistics reported by the 
QCR, defined as all invasive cancers with International Classification of Diseases for Oncology 3 
(ICD-O3) site codes C00 to C80 (excluding C44 morphology codes M805 to M811, as these code 
for BCC and SCC).27 
 
Sixteen benign or non-invasive neoplasms (i.e. with ICD-O behaviour codes of 0, 1, or 2) with 
histopathology confirmation were thus excluded. 
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Excluded neoplasms were two monoclonal gammopathies of unknown significance in two males 
both affected by melanoma, one parathyroid adenoma in a male FDR, one vulva intraepithelial 
neoplasia (VIN) III in a female FDR, one cervical intraepithelial neoplasia (CIN) I in a female 
FDR, one CIN II bordering on CIN III in a female affected by melanoma, and six cases of CIN 
III/cervical SCC in situ (five females affected by melanoma, and one FDR). 
 
Four WHO grade I brain neoplasms were also excluded: one fibroblastic meningioma in a female 
FDR, one fibroblastic meningothelial meningioma in a male affected by melanoma, one 
meningothelial meningioma in a female FDR, and one haemangioblastoma cerebellum in a male 
FDR. 
 
Cancer risk estimates 
 
The Cancer Council Queensland publishes annual incidence of all invasive cancers, and also 
publishes a standardised incidence rate per 100,000 people for males, females, and total population. 
Annual crude incidence rates for each age and sex stratum are calculated and then applied to a 
standard reference population, to allow direct comparison and averages between years. 
 
The standard population used for calculating age-standardised incidence rates by the Cancer 
Council Queensland is the 2001 Australian resident population, as published by the Australian 
Bureau of Statistics. 
 
Based on differences in the availability of cancer incidence rates subdivided by age and sex for the 
study population at different periods of time, there are thus multiple valid ways that risk estimates 
can be derived. Cancer incidence rates are reported in the following ways: an average of incidence 
rates from 2008 to 2012, reported in 5 year age groups up to 85 years and over for males and 
females; and cancer incidence rates for each year from 1982 to 2012, reported in 15 year age groups 
from 35 years to 80 years and over in males and females for some cancers, and by sex only for 
remaining cancers. We present here data derived using two approaches: firstly based on the 
population statistics for the period 2008-2012; and secondly, for the period 1982-2012. 
 
Method 1: 2008-2012 
 
The expected number of cancers was calculated from age and sex specific published cancer 
incidence rates for Queensland. This was calculated first for all cancers using the 2008 to 2012 
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average incidence rate, age standardised in 5-year age groups from 0 up to 85 years and over [28]. 
Incidence rates expressed as a number of events per 100,000 people were divided by 100,000 and 
multiplied by the number of person years under observation in each age and sex specific stratum. 
The resulting numbers for each stratum were added to obtain ‘expected’ cancer events in the cohort 
and sub-groups for each cancer type. 
 
 
Method 2: 1982-2012 
 
The average of the cancer incidence over this time period was calculated, as the sum total divided 
by 31, reflecting 31 years of data.29 As for Method 1, average incidence rates were divided by 
100,000 and then multiplied by the number of person years in each age and sex stratum of the study 
cohort. For cancers where age stratified data were available (all invasive cancers, melanoma – used 
only in context of removing this number from total invasive cancers, breast, cervical, colorectal, 
lung, non-Hodgkin lymphoma (NHL), and prostate cancer), published cancer incidence rates per 
100,000 persons for age groupings of age 35-49, age 50-64, age 65-79, and age 80 and over were 
used. No incidence rates were reported for the ages of 0 to 34. Therefore, to account for cancer 
events in persons aged 34 and younger, expected cancers for 0 to 34-year-olds were calculated by 5-
year age groups from the published 2008-2012 incidence rates, and added to the total of expected 
cancers for age 35 to 80 years and over from 1982-2012 incidence rates. 
 
For cancers where incidence rate data from 1982 to 2012 per 100,000 persons was only available 
for sex, and not stratified by age (bladder, brain, head and neck, gynaecological – combined group, 
ovarian, uterine, kidney, leukaemia - combined group, lymphoid leukaemia, myeloid leukaemia, 
lymphoma – combined Hodgkin lymphoma and NHL, myeloma, liver, mesothelioma, pancreatic, 
stomach, and thyroid cancer), cancer risk estimates were obtained by multiplying the average total 
incidence for males and females by the number of person years under observation. 
  
Statistical analysis 
 
The standardised incidence ratio (SIR) was computed as the ratio of observed and expected cases of 
cancer. As above, expected cancers were based on age and sex specific incidence rates multiplied 
by the number of person years in each age and sex specific stratum. A person year was defined as 
any part of a year under observation while the person was alive, with a maximum of 33 years from 
1982 to 2014 inclusive. 95% confidence intervals were computed to test the statistical significance 
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of the SIRs, based on the Poisson distribution model. The difference between observed and 
expected cases was considered statistically significant if the 95% confidence interval did not 
include the value of 1. 
 
Expected versus observed cancers and 95% confidence intervals were calculated by sex and by sub-
group for individuals affected by melanoma and FDRs. 
 
Age and sex standardized ‘expected’ events of melanoma were calculated for the purpose of 
subtracting these from the total number of expected invasive cancers, to obtain the expected number 
of invasive non-melanoma cancers. Melanoma risk was not analysed, as families were selected 
based on ‘intermediate risk’ melanoma status. 
 
RESULTS 
 
A total of 943 individuals from 178 families were included, comprising 25,264 person years of 
observation. There were 414 individuals affected by melanoma, 192 males and 222 females, with 
5,244 and 6,722 person years of observation, respectively. There were 529 FDRs of these 
individuals, 250 males and 279 females, contributing 5873 and 7425 person years, respectively.  
  
Of the 178 families, 125 (70%) had at least one individual diagnosed with non-melanoma cancer 
during the study period. 
 
Of 414 individuals affected by melanoma, there were 128 non-melanoma cancer events in 102 
(25%) individuals. Of the FDRs, 134 (25%) were also diagnosed with at least one non-melanoma 
cancer, with a total of 150 non-melanoma cancer events in this group. 
 
The observed versus expected cancers were analysed in two different ways, as outlined in the 
methods. 
 
2008 to 2012 incidence rates 
 
Using the 2008 to 2012 incidence rates, in the overall cohort there was not a statistically 
significantly different number of total cancers observed than expected (observed, 278; expected, 
291.43; SIR, 0.95; 95% CI 0.85-1.07). Bladder, haematological, and thyroid malignancies were 
modestly increased (Table 3). 
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When separated by sex, no cancers reached statistical significance in males (Table 4). In females, 
increases in observed numbers of bladder cancer (observed, 7; expected, 1.99; SIR, 3.52; 95% CI, 
1.41-7.25) and lymphoid leukaemia (observed, 6; expected, 1.75; SIR, 3.43; 95% CI, 1.26-7.46) 
were statistically significant (Table 5; Figure 6).  
  
Considering the individuals with melanoma separately, myeloma was statistically significant for the 
overall group (observed, 6; expected, 1.97; SIR, 3.04; 95% CI 1.12-6.62). However, when separated 
by sex, myeloma was only significant for females (observed, 4; expected, 0.82; SIR, 4.89; 95% CI 
1.33- 12.52). Bladder cancer was also statistically significant for females affected by melanoma 
(observed, 4; expected, 0.87; SIR, 4.59; 95% CI, 1.25-11.76). There were slightly more renal, 
haematological, and thyroid cancers than expected in melanoma cases, but these cancers did not 
reach statistical significance. 
  
In FDRs of individuals with melanoma, either as a combined group or stratified by sex, no cancers 
reached statistical significance. 
 
1982 to 2012 incidence rates 
 
Comparing the study population to the average age and sex standardised incidence rates from 1982 
to 2012, observed versus expected total non-melanoma invasive cancers was not significantly 
increased (observed, 278; expected, 267.30; SIR 1.04; 95% CI 0.92-1.17). 
 
For cancers with available age and sex standardised incidence rates, there were modest increases in 
observed events of NHL (16 observed, 9.71 expected) and female breast cancer (40 observed, 31.79 
expected), however these differences were not statistically significant. 
 
The remainder of cancers had incidence rates for males and females (available as an incidence rate 
by sex only) from 1982 to 2012. A number of cancers reached statistical significance for males and 
females combined – bladder, kidney, leukaemia, lymphoid leukaemia, lymphoma, myeloma, 
mesothelioma, pancreas, and thyroid (Table 3). 
 
Statistically significant cancers with more than ten observed events each were bladder cancer 
(observed, 12; expected 3.93; SIR, 3.05; 95% CI, 1.58-5.33), leukaemia, mostly comprised of 
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lymphoid leukaemia (observed, 12; expected 3.73; SIR, 3.22; 95% CI, 1.66-5.63), and lymphoma 
(observed, 17; expected 4.63; SIR, 3.68; 95% CI, 2.14-5.88). 
 
The only cancers with at least five events to be statistically significant in males only were 
lymphoma, with 9 observed and 2.38 expected cases (SIR, 3.78, 95% CI 1.73-7.18), and kidney 
cancer, with 7 observed and 1.85 expected cases (SIR, 3.78; 95% CI 1.52-7.79) (Table 4; Figure 7). 
 
In females, bladder cancer (observed, 7; expected, 0.98; SIR 7.12; 95% CI 2.86-14.66), thyroid 
cancer (observed, 5; expected, 1.30; SIR, 3.85; 95% CI, 1.25-8.99), and haematological 
malignancies were statistically significant. Leukaemia (observed, 7; expected, 1.59; SIR, 4.40; 95% 
CI, 1.77-9.07), including lymphoid leukaemia (observed, 6; expected, 0.77; SIR, 7.81; 95% CI, 
2.87-17.00), lymphoma (observed, 8; expected, 2.21; SIR, 3.62; 95% CI, 1.56-7.14), and myeloma 
(observed, 4; expected, 0.62; SIR, 6.43; 95% CI, 1.75-16.47) were also all statistically significant 
(Table 5; Figure 7). 
 
Lymphoid leukaemia was significant both for females affected by melanoma and female FDRs. 
Lymphoma and myeloma remained statistically significant when considering females affected by 
melanoma separately, but were not significant for FDRs. 
 
Brain cancer was increased for females in the group (observed, 4; expected, 0.82; SIR 4.87; 95% CI 
1.33-12.46), mostly owing to female FDRs. 
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Table 3: Observed versus expected invasive cancers, combined male and female 
  1982-2012* 2008-2012 
Cancer site/type Observed Expected SIR 95% CI Expected SIR 95% CI 
All invasive non-
melanoma 
278 267.30 1.04 0.92-1.17 291.43 0.95 0.85-1.07 
Bladder 12 3.93 3.05 1.58-5.33 7.71 1.56 0.80-2.72 
Brain 5 1.76 2.84 0.92-6.64 3.50 1.43 0.46-3.33 
Breast 40 31.79 1.26 0.90-1.71 36.70 1.09 0.78-1.48 
Colorectal 34 42.92 0.79 0.55-1.11 43.34 0.78 0.54-1.10 
Gynaecological 8 6.17 1.30 0.56-2.56 12.66 0.63 0.66-1.95 
Cervical 2 2.54 0.79 0.10-2.85 1.58 1.27 2.19-9.98 
Ovarian 2 1.73 1.16 0.14-4.18 3.51 0.57 0.07-2.06 
Uterine 3 2.17 1.38 0.28-4.04 5.90 0.51 0.10-1.49 
Leukaemia (all) 12 3.73 3.22 1.66-5.63 9.25 1.30 0.67-2.27 
Lymphoid leukaemia 8 1.80 4.44 1.92-8.75 4.37 1.83 0.79-3.61 
Myeloid leukaemia 4 1.53 2.62 0.71-6.70 3.24 1.23 0.19-2.71 
Lymphoma (all) 17 4.63 3.68 2.14-5.88 12.57 1.35 0.79-2.17 
NHL 16 9.71 1.65 0.94-2.68 11.84 1.35 0.77-2.19 
Myeloma 6 1.39 4.32 1.59-9.40 4.20 1.43 0.52-3.11 
Head and neck 6 3.90 1.54 0.56-3.35 8.76 0.68 0.25-1.49 
Kidney 9 3.25 2.77 1.27-5.26 9.38 0.96 0.44-1.82 
Liver 2 0.89 2.26 0.27-8.15 3.51 0.57 0.07-2.06 
Lung 27 31.45 0.86 0.57-1.25 32.35 0.83 0.55-1.21 
Mesothelioma 3 0.53 5.71 1.18-16.68 2.35 1.28 0.26-3.73 
Pancreatic 7 2.50 2.80 1.13-5.78 7.51 0.93 0.37-1.92 
Prostate 49 44.29 1.11 0.82-1.46 54.53 0.90 0.66-1.19 
Stomach 4 2.68 1.49 0.41-3.82 5.16 0.78 0.21-1.98 
Thyroid 7 1.57 4.45 1.79-9.17 4.27 1.64 0.66-3.38 
Bold type indicates statistical significance. 
SIR: standardised incidence ratio, calculated as observed/expected; NHL: non-Hodgkin lymphoma 
* Expected cancers standardized by age and sex: all invasive cancers, breast, cervical, colorectal, lung, NHL, 
and prostate cancer. 
Expected cancers standardised by sex only: bladder, brain, head and neck, gynaecological – combined group, 
ovarian, uterine, kidney, leukaemia - combined group, lymphoid leukaemia, myeloid leukaemia, lymphoma – 
combined Hodgkin lymphoma and NHL, myeloma, liver, mesothelioma, pancreatic, stomach, and thyroid 
cancer 
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Table 4: Observed versus expected invasive cancers, males 
  1982-2012* 2008-2012 
Cancer site/type Observed Expected SIR 95% CI Expected SIR 95% CI 
All invasive non-
melanoma 
156 155.75 1.00 0.85-1.17 164.86 0.95 0.80-1.11 
Bladder 5 2.94 1.70 0.55-3.97 5.77 0.87 0.28-2.02 
Brain 1 0.91 1.10 0.03-6.13 1.88 0.53 0.01-2.96 
Breast 2       
Colorectal 24 22.88 1.05 0.67-1.56 23.10 1.04 0.67-1.55 
Leukaemia (all) 5 2.11 2.37 0.77-5.75 5.53 0.90 0.29-2.11 
Lymphoid leukaemia 2 1.01 1.98 0.24-7.14 2.59 0.77 0.09-2.79 
Myeloid leukaemia 3 0.84 3.55 0.73-10.39 1.85 1.62 0.33-4.74 
Lymphoma (all) 9 2.38 3.78 1.73-7.18 6.94 1.30 0.59-2.46 
NHL 8 5.15 1.55 0.67-3.06 6.58 1.22 0.52-2.40 
Myeloma 2 0.77 2.59 0.31-9.37 2.40 0.83 0.10-3.01 
Head and neck 4 2.70 1.48 0.40-3.80 6.19 0.65 0.18-1.65 
Kidney 7 1.85 3.78 1.52-7.79 5.56 1.26 0.51-2.59 
Liver 1 0.59 1.69 0.04-9.39 2.40 0.42 0.01-2.32 
Lung 19 22.63 0.84 0.51-1.31 19.85 0.96 0.58-1.49 
Mesothelioma 3 0.49 6.18 1.27-18.06 1.93 1.55 0.32-4.54 
Pancreatic 4 1.29 3.11 0.85-7.97 3.73 1.07 0.29-2.75 
Prostate 49 44.29 1.11 0.82-1.46 54.53 0.90 0.66-1.19 
Stomach 3 1.74 1.72 0.36-5.04 3.34 0.90 0.19-2.62 
Thyroid 2 0.37 5.46 0.66-19.71 1.16 1.72 0.21-6.23 
Bold type indicates statistical significance. 
SIR: standardised incidence ratio, calculated as observed/expected; NHL: non-Hodgkin lymphoma 
* Expected cancers standardized by age and sex: all invasive cancers, breast, cervical, colorectal, lung, NHL, and 
prostate cancer. 
Expected cancers standardised by sex only: bladder, brain, head and neck, kidney, leukaemia - combined group, 
lymphoid leukaemia, myeloid leukaemia, lymphoma – combined Hodgkin lymphoma and NHL, myeloma, liver, 
mesothelioma, pancreatic, stomach, and thyroid cancer 
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Table 5: Observed versus expected invasive cancers, females 
  1982-2012* 2008-2012 
Cancer site/type Observed Expected SIR 95% CI Expected SIR 95% CI 
All invasive non-
melanoma 
122 115.24 1.06 0.88-1.26 126.14 0.97 0.80-1.15 
Bladder 7 0.98 7.12 2.86-14.67 1.99 3.52 1.41-7.25 
Brain 4 0.82 4.87 1.33-12.46 1.60 2.50 0.68-6.40 
Breast 40 31.79 1.26 0.90-1.71 36.70 1.09 0.78-1.48 
Colorectal 10 20.03 0.50 0.24-0.92 20.03 0.50 0.24-0.92 
Gynaecological 8 6.17 1.30 0.56-2.56 12.66 0.63 0.27-1.25 
Cervical 2 0.98 2.03 0.25-7.34 1.58 1.27 0.15-4.57 
Ovarian 2 1.73 1.16 0.14-4.18 3.51 0.57 0.07-2.06 
Uterine 3 2.17 1.38 0.28-4.04 5.90 0.51 0.10-1.49 
Leukaemia (all) 7 1.59 4.41 1.77-9.08 3.69 1.90 0.76-3.91 
Lymphoid leukaemia 6 0.77 7.81 2.87-17.00 1.75 3.43 1.26-7.46 
Myeloid leukaemia 1 0.69 1.45 0.04-8.09 1.39 0.72 0.02-4.01 
Lymphoma (all) 8 2.21 3.62 1.56-7.14 5.56 1.44 0.62-2.84 
NHL 8 4.57 1.75 0.76-3.45 5.21 1.54 0.66-3.03 
Myeloma 4 0.62 6.43 1.75-16.47 1.81 2.21 0.60-5.66 
Head and neck 2 1.02 1.95 0.24-7.06 2.33 0.86 0.10-3.10 
Kidney 2 1.34 1.49 0.18-5.39 3.72 0.54 0.07-1.94 
Liver 1 0.27 3.70 0.09-20.63 1.04 0.96 0.02-5.36 
Lung 8 9.23 0.87 0.37-1.71 12.55 0.64 0.28-1.26 
Mesothelioma 0 0.89 - - 0.43 - - 
Pancreatic 3 1.19 2.53 0.52-7.40 3.73 0.80 0.17-2.35 
Prostate        
Stomach 1 0.92 1.09 0.03-6.07 1.78 0.56 0.01-3.13 
Thyroid 5 1.30 3.85 1.25-8.99 3.32 1.51 0.49-3.51 
Bold type indicates statistical significance. 
SIR: standardised incidence ratio, calculated as observed/expected; NHL: non-Hodgkin lymphoma 
* Expected cancers standardized by age and sex: all invasive cancers, breast, cervical, colorectal, lung, and NHL. 
Expected cancers standardised by sex only: bladder, brain, head and neck, gynaecological – combined group, 
ovarian, uterine, kidney, leukaemia - combined group, lymphoid leukaemia, myeloid leukaemia, lymphoma – 
combined Hodgkin lymphoma and NHL, myeloma, liver, mesothelioma, pancreatic, stomach, and thyroid cancer 
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Figure 6. Frequency of cancers with 3 observed events, for males and females, ranked in order of 
significance from 2008-2012 analysis. The position of statistically significant cancers corresponds 
to the odds ratios for each cancer type, indicated by numbered values on the positive y axis. Cancers 
that were not statistically significant are ranked in order of decreasing odds ratios on the negative y 
axis. The values on the x axis indicate frequency of cancer. CRC: colorectal cancer; NHL: non-
Hodgkin lymphoma. 
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Figure 7. Frequency of cancers with 3 observed events, for males and females, ranked in order of 
significance from 1982-2012 analysis. The position of statistically significant cancers corresponds 
to the odds ratios for each cancer type, indicated by numbered values on the positive y axis. Cancers 
that were not statistically significant are ranked in order of decreasing odds ratios on the negative y 
axis. The values on the x axis indicate frequency of cancer. CRC: colorectal cancer; NHL: non-
Hodgkin lymphoma. Expected cancers standardized by age and sex: all invasive cancers, breast, 
cervical, colorectal, lung, NHL, and prostate cancer. Expected cancers standardised by sex only: 
bladder, brain, head and neck, gynaecological – combined group, ovarian, uterine, kidney, 
leukaemia - combined group, lymphoid leukaemia, myeloid leukaemia, lymphoma – combined 
Hodgkin lymphoma and NHL, myeloma, liver, mesothelioma, pancreatic, stomach, and thyroid 
cancer. 
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DISCUSSION 
 
This study investigated cancer in 178 ‘intermediate risk’ melanoma families, not selected for 
genetic mutations. The main finding of this present analysis is the significance of bladder cancer 
and lymphoid leukaemia in females of the cohort, and myeloma in females affected by melanoma. 
 
A greater number of other cancers were significant in the 1982-2012 analysis. However, the non-
age standardised results must be interpreted with caution due to differences in the age distribution 
of the 2001 standard population and the study cohort population. While the 2008-2012 data is more 
precise due to narrower bands of age standardisation, the 1982-2012 method may reveal differences 
in cancer incidence and population trends over time that is more representative of the study 
population. Incidence counts of invasive cancer in Queensland have increased since 1982, and 
remain elevated even when standardised against a reference population to account for the changing 
demographics of an ‘aging’ population with more cancer events in older Australians.29 Incidence 
rates of different cancers have also varied over the study period, possibly reflecting environmental 
and screening factors.30 It is likely that the ‘real’ value falls somewhere between the estimates from 
the two methods. 
 
Significant cancers 
 
Bladder 
 
Reports of a possible association between risks of bladder cancer and melanoma are varied, 
although one population-based study found it to be the only significant non-melanoma cancer in 
relatives of individuals with multiple primary melanomas.1, 31 Cases of bladder cancer have been 
documented in melanoma families affected by mutations in MITF, TERT, and BAP1, but a heritable 
link between these cancer types has not been proven.20, 25, 32 Telomerase reverse transcriptase 
(TERT) gene promoter mutations initially described in melanoma have since been identified in 
bladder cancer, including a rare segregating variant initially found in a large melanoma family.32 
This T>G variant, located -59 base pairs from the ATG translation start site of TERT, generated 
binding motifs for Ets and ternary complex transcription factors, and has since been noted in a 
bladder tumour.33 A recent study identified germline single nucleotide substitutions in the proximal 
promoter of TERT in more than 50% of bladder tumours, including some that were also confirmed 
as somatic in distinct tumours.34 The frequency (more than two-thirds) of somatic alterations in a 
variety of tumour stages suggests that TERT promoter alterations may be a common early event in 
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bladder tumorigenesis.33-35 Somatic alterations in BAP1 were also recently detected in 15% of 
bladder tumours.34 Although multiple susceptibility loci have been proposed, segregating germline 
bladder cancer mutations are infrequently reported.36 Several multiple-case bladder cancer families 
contain individuals with other cancers, but there seem no specific sites or inheritance modes.37 In a 
two-case bladder cancer family, a novel germline balanced translocation affecting expression of 
CDC91L1 at 20q11 was found in a 29-year-old male with bladder and renal pelvis transitional cell 
carcinoma.38 In addition to a father with prostate cancer, the proband also had a brother who died at 
age 27 of metastatic melanoma. Given the young age of diagnosis in both brothers with bladder 
cancer and melanoma, it is plausible that this represents an extremely rare germline variant 
predisposing to both tumours. Over-expression of the cell division cycle 91-like 1 (CDC91L1) 
protein (75%) and micro-RNA (30%) in bladder cancer has subsequently been found in primary 
bladder carcinomas and cell lines.39 In our study, more women than men were affected by bladder 
cancer, in contrast to higher population incidence in men worldwide. Tobacco smoke exposure that 
was historically biased toward men has now equalised, and despite the known vulnerability of 
bladder tissue to smoking, rates of male and female cancer have not matched modern smoking 
trends.40 Causes of bladder cancer in women specifically have been inconclusive, with varying 
reports on parity, menopause, and hormone replacement therapy.41 
 
Lymphoid leukaemia 
 
A bidirectional association between melanoma and leukaemia has been established, and melanoma 
risk following CLL appears particularly increased in the Australian population.42-45 A host of 
factors including environmental ultraviolet light exposure, chronic immunosuppression, and genetic 
components have been proposed.42 Although lymphoid leukaemia has a strong genetic component 
for concordant cancer, linkage studies have failed to account for familial risk. However, a number 
of SNPs have demonstrated significance, and it is proposed that familial and sporadic CLL share 
many common elements. One novel variant allele, of DAPK1 at chromosome band 9q22, was found 
to segregate with CLL in a six-case family, and was initially considered a private mutation until 
recent detection of germline DAPK1 allele-specific expression in 14% of tested CLL cases.46, 47 A 
link between melanoma and CLL has been identified following the discovery of a shared mutation 
in POT1, in the germline of a melanoma family and somatically in CLL.21, 48 One POT1 germline 
mutation carrier had a history of both cancers, and it is possible that a common variant could 
influence cancer pathways for both melanoma and leukaemia.21, 22, 48 Like POT1, the recently 
identified melanoma predisposition gene ACD is also involved in maintenance of telomere length as 
part of the shelterin complex, and the presence of both melanoma and leukaemia in an ACD 
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mutation carrier could feasibly represent a shared link.49 An over-representation of females with 
lymphoid leukaemia in our cohort may be explained by a finding of a greater affected proportion of 
females with familial CLL compared to sporadic CLL. It is projected that sex specific differences in 
penetrance or modifiers may be a feature of the discrepancy.50 
 
Myeloma 
 
A significantly increased risk of myeloma for FDRs of melanoma cases has been noted in both the 
Utah and Swedish population databases, although the reverse has not been detected in familial 
multiple myeloma.1, 2, 51, 52 Studies on familial clustering of myeloma have demonstrated increased 
risk of concordant cancer, as well as leukaemia (particularly CLL), and a common aetiologic 
pattern for the clustering of these cancers has been proposed.51, 52 Other cancers linked to familial 
myeloma include colorectal, breast, non-thyroid endocrine, and prostate cancer.52 A higher risk of 
myeloma has been identified for daughters of affected cases, with the highest risk in daughters of 
affected mothers (SIR 4.58).51 This sex correlation replicates previous results, and a female 
predilection possibly represents a heritable sex-specific modifier or common susceptibility, which 
may explain the findings of significance for females only in our cohort.51 Most family studies 
suggest an autosomal dominant mode of inheritance, with low penetrance for myeloma.52 A genetic 
link between myeloma and melanoma has been established in one family, suggesting the high 
penetrance melanoma risk gene CDKN2A also acts as a low penetrance susceptibility gene for 
myeloma.53 In this study, a germline CDKN2A mutation was present in four family members with 
melanoma and one with myeloma, and loss of heterozygosity studies on bone marrow of the 
individual affected by myeloma demonstrated loss of the wild-type CDKN2A allele in malignant 
plasma cells.53 Of seven other risk loci predisposing to myeloma, two have possible links to 
melanoma.54-56 A telomere link may be plausible via a SNP at 3q26.2 mapping 5’ to the gene 
encoding the telomere RNA component (TERC) that helps maintain telomere ends in combination 
with TERT, a known high penetrance melanoma gene.55 A common mechanism via the 
p16INK4a/Rb and ARF/p53 pathways may also exist, as a SNP at 22q13.1 localising to chromobox 
homolog 7 (CBX7) influences these pathways through cooperation with the oncogene MYC.55 A 
study of temporal associations between myeloma and other neoplasms identified 5 cases of 
melanoma and myeloma in the same individuals, with a median time of 5 years between melanoma 
and myeloma being diagnosed.57 
 
Additional neoplasms in the same individual are important to consider not only in the context of 
heritable risk factors, but also in relation to the possible contribution of the primary cancer to the 
 49 
development of a subsequent cancer. Field cancerisation from treatment with radiation and 
chemotherapy has been associated with ensuing haematological malignancies, and also radiation-
sensitive tissue like breast and thyroid.58 However, a radiation-induced effect in our cohort seems 
unlikely given that surgery is the main treatment for melanoma, and the relatively long time from 
melanoma to diagnosis of first haematological malignancy (median 18.5 years). The development 
of CLL or NHL in a study of melanoma patients treated with surgery only suggests that the 
association is unrelated to prior treatment, consistent with reports of CLL as non-radiogenic.59, 60 
Myeloma has also not been reliably associated with radiotherapy.61 It is likely that multiple 
neoplasms in the same individual are related to an underlying predisposition for cancer comprised 
of genetic and non-radiation environmental factors. 
 
MULTIPLE CANCERS 
 
Further to statistically significant cancers, the presence of multiple cancers in some families and 
individuals is of interest. Fifteen individuals had three different types of cancer – at least one 
melanoma, and at least two other types of invasive cancer (Table 6).  
 
Table 6   Individuals affected by melanoma and at least two other invasive cancers, in order of diagnosis 
First cancer Second cancer Third cancer Fourth cancer Fifth cancer 
Females 
Melanoma CLL NHL - - 
Melanoma x 4 Endometrial Thyroid - - 
Melanoma Breast Myeloma - - 
Melanoma Breast CRC - - 
Melanoma NHL CLL - - 
Melanoma Myeloma CML - - 
Males 
Thyroid Melanoma RCC - - 
RCC Prostate Melanoma - - 
Prostate Breast Parotid Melanoma - 
Melanoma Prostate Mesothelioma - - 
Melanoma NHL RCC CRC Prostate 
Melanoma x 2 Hodgkin 
Lymphoma 
CML - - 
Melanoma Prostate NHL CLL - 
Melanoma x4 CRC Gallbladder - - 
Melanoma CRC AML - - 
AML: acute myeloid leukaemia; CLL: chronic lymphocytic leukaemia; CML: chronic myeloid leukaemia; 
CRC: colorectal cancer; NHL: non-Hodgkin lymphoma; RCC: renal cell carcinoma 
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Relatively uncommon cancers that were observed in these individuals include renal cell carcinoma, 
mesothelioma, and cholangiocarcinoma (interestingly, all cancers that are associated with BAP1 
germline mutations), and thyroid cancer. Eight of 15 individuals had a haematological malignancy, 
including six leukaemias (three lymphoid leukaemia, and three myeloid leukaemia). 
 
In sixteen melanoma-dense families, with four or more individuals affected by melanoma, 15 
families had at least one individual affected by another type of invasive cancer. These cancers 
included bladder, breast, glioma, lymphoid leukaemia, lymphoma, mesothelioma, and kidney 
cancer. Although few in number, the presence of bladder cancer, lymphoid leukaemia, and 
myeloma in melanoma-dense families supports the possibility of common risk polymorphisms 
shared by these cancer types. Common polymorphisms predisposing to cancer in general are also 
supported by the presence of more common cancers in these families, in contrast to the cohort 
findings. Of the 16 families, eight had at least one case of prostate cancer, six had colorectal cancer, 
six had lung cancer, and five had breast cancer. Of three mesothelioma events in the cohort, two 
were in cancer-dense families (a five-case family, and a six-case family). Although the numbers are 
too few to be statistically relevant at a population level, the cancer density (and types) of these 
families warrants further investigation for potential germline mutations, particularly in BAP1. 
 
Compared with cancer associations for known high penetrance melanoma genes, the seven 
observed pancreatic cancers were not significant by age standardised analysis, which contrasts with 
the frequency of pancreatic cancer in CDKN2A mutation-positive families. As CDKN2A is the most 
common high penetrance mutation, it seems that more pancreatic cancer would be expected, 
however this finding may be consistent with Australian data that demonstrates fewer cases of 
pancreatic cancer in CDKN2A families than international counterparts.1, 11, 12, 62 It also echoes the 
findings in the Utah population, where pancreatic cancer was not increased. Suggested contributing 
factors are the relatively low number of families affected by CDKN2A mutations, and the 
heterogeneity of pancreatic cancer predisposition in families that do carry CDKN2A mutations.1, 5 
 
Further to pancreatic cancer, the present study has not demonstrated associations for all significant 
cancer types found in population studies of melanoma families. It is possible that the sample size 
has been too small to detect an association, but also that a difference in the low risk genetic 
polymorphisms and environmental exposures of the Queensland study population predisposes to 
specific cancer types. Although this study reflects population level cancer risk, it is also possible 
that some cancers may be attributed to a small number of families with undetected mutations in 
high-penetrance melanoma predisposition genes.  
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CONCLUSION 
 
This pilot hypothesis-generating study demonstrates a possible link between melanoma and other 
cancers in individuals affected by melanoma and their FDRs, particularly bladder cancer and 
lymphoid leukaemia in females, and multiple myeloma in females affected by melanoma. 
Associations we have found here for the above over-represented cancers require replication and 
validation in an independent data set. 
 
An over-representation of other cancers in melanoma families hints at the possibility of common 
pathways for oncogenesis, including a likely multi-hit model of many low risk heritable 
polymorphisms and other modifiers that underpin susceptibility to invasive malignancies. 
 
It is possible to conduct genetic testing for known high penetrance germline mutations predisposing 
to melanoma, however the low yield at a population level and likely polygenic risk modification 
raises questions about clinical utility.  Although estimating a polygenic risk score has been 
proposed, incomplete penetrance and multiple environmental modifiers and other lifetime exposure 
risks create difficulty in translating plausible associations to clinical benefit. The main implication 
for clinical application of familial cancer association research at the population level is likely in the 
field of primary health care, in providing appropriate counselling and information regarding cancer 
risk and prevention strategies for cancers linked to familial melanoma. 
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Chapter 4 
 
Investigation of the mutational landscape in high case density melanoma families and 
individuals with three or more invasive cancer types 
 
INTRODUCTION 
 
For families in the cohort described in Chapter 3 with a high case density of melanoma, the 
presence of heritable germline variants may be an important component of cancer susceptibility.  
Melanoma predisposition for some families is linked to mutations in known high penetrance 
melanoma risk genes, as discussed in Chapter 2. However, the number of families that do not carry 
a known high penetrance mutation infers that even in those with a relatively high melanoma case 
density, it is likely that multiple novel and rare germline mutations of low to moderate penetrance 
collectively raise overall familial cancer susceptibility. Further to melanoma, the contribution of 
‘melanoma’ risk genes to other cancer types is increasingly evident. For individuals with multiple 
cancer types including melanoma, it is plausible that mutations affecting common pathways in 
oncogenesis predispose to a variety of tumour types. To assess the possible contribution of germline 
mutations to melanoma predisposition and also other cancers, we used whole exome sequencing 
(WES) to analyse DNA from individuals in eight families with a high melanoma case density, and 
eleven individuals with three or more types of invasive cancer. 
 
MATERIALS AND METHODS 
 
Study inclusion 
 
The study cohort of 178 families was ascertained from the QFMP, as discussed in Chapter 2. 
Families were selected for WES on the basis of high melanoma case density, defined as four or 
more family members with melanoma, and then further prioritized on the basis of family bloodline, 
relatively young age of onset, multiple primary melanomas, presence of other cancers previously 
associated with melanoma, and availability of DNA samples for melanoma cases. Families 
remained designated as ‘intermediate risk’ as per the original study, regardless of subsequent new 
cases of melanoma. Individuals from the 178 families were selected for WES on the basis of three 
or more cancer types including melanoma in a single individual. Individuals with young age of 
onset, multiple primary melanomas, uncommon cancer types, or more than three different cancer 
types were prioritised for whole genome sequencing (WGS). 
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DNA samples 
 
DNA samples from whole blood were obtained with consent as part of the original QFMP project 
and stored at QIMR Berghofer. Only existing samples were sent for sequencing. 
 
Whole-exome sequencing and data analysis 
 
WES for six cases using the SureSelectXT Target Enrichment System for Illumina Version B.2, and 
WGS for five cases, was conducted using the HiSeq 4000 platform. Paired-end reads of 75-100 bp 
were generated, with mean coverage of 60-96X. 
 
Aligning Reads (fastq ! bam) 
Raw sequence reads (in fastq format) were aligned to the human reference genome (hg19) using the 
Burrows-Wheeler Aligner.1 Reads were adjusted to conform to standard SAM format using an in-
house tool*, reads were sorted with respect to genomic coordinate using samtools, duplicate reads 
marked with Picard, and reads were re-aligned against known indels and base qualities were re-
calibrated using the Genome Analysis Toolkit.2, 3 
 
Calling SNVs and small indels (bam ! vcf) 
Raw variants were detected using samtools and bcftools.4 Variant Indels were verified in silico† and 
double-nucleotide variants detected and phased using in-house tools‡. Variants were fully annotated 
with ANNOVAR including dbSNP as well as allele frequencies from 1000 Genomes Project and 
NHLBI Exome Sequencing Project.5 ANNOVAR also provides predictions of the effect the variant 
might have on the encoded protein including predictions from Sorting Intolerant from Tolerant 
(SIFT), Polymorphism Phenotyping v2 (PolyPhen2), Gerp++, LRT, MutationTaster, and PhyloP. 
 
Analysis of candidate genes 
 
Variants were separated into two groups: novel and rare. Novel variants had never been observed in 
the dbSNP or ESP6500 databases, whereas rare exonic variants had been previously observed at a 
frequency of <1% in either dbSNP or ESP6500. Candidate novel and rare segregating variants were 
identified and prioritised by known existing roles as melanoma predisposition genes, genes known 
                                                
* Mapping quality is set to zero and CIGAR is set to empty. 
† Reads overlapping with indel are aligned against candidate alleles, reads that have a significant best alignment are 
counted, and allele counts (AD) in VCF are updated. 
‡ Adjacent SNVs are identified and reads are interrogated to determine genotype, counts, and likelihoods.!
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to be somatically mutated in melanoma or other cancers, and genes known to predispose to other 
cancers. For all novel and rare segregating variants designated as ‘damaging’ by SIFT, ‘damaging’ 
or ‘probably damaging’ by PolyPhen2, or ‘disease causing’ by MutationTaster programs, the genes 
were referenced against the NCBI gene database to assess potential contribution to cancer. Variants 
with a total count that was higher than the number of sequenced individuals in each family were 
excluded, to minimise confounding by errors in sequencing or sequence tag alignment. 
 
RESULTS 
 
Eight families were selected for WES. Each family had four or more melanoma cases, and at least 
three individuals with DNA samples available. A total of 15 novel segregating exonic variants and 
one novel segregating splicing variant were identified in seven families. 
 
Novel variants that segregated were identified in the genes MAGI1, MAP4K4, MCC, and ROS1 in 
family 007178; DGKA, DUSP27, and SOX1 in a three-case bloodline subgroup of family 010482, 
and PARK7 in a four-case bloodline subgroup of the same family; SETD5 and TP53BP1 in family 
012081; NEK7 in family 012828; ERCC3 in family 050904; MACF1, MX2, and TNK2 in family 
051656; and GRIN2C in family 052448.  
 
Rare segregating variants in known cancer genes or possible cancer genes were found in family 
007178 (ERBB3, MAP3K6, EDNRB); the 3 case subgroup of family 010482 (CKAP2, HUS1, 
PDZD2); the 4 case subgroup of family 010482 (MAP3K11); family 050904 (ABCB5, MUTYH); 
family 051656 (FANCI, KDM1B, PML, SLK, WWOX); and family 052448 (TYRP1). Novel and rare 
variants that did not segregate were identified in other families. 
 
Fifteen individuals affected by at least three invasive cancer types including melanoma were 
identified in the study cohort, six females and nine males. Three individuals who had not provided a 
DNA sample were excluded, as was an individual whose sample could not be located. Twenty-nine 
genes of interest containing novel variants were identified, including several genes (APC, CDH1, 
MAGI1, MAP3K13, MAP3K4, PLK5, and POLD1) with novel variants in two or more individuals 
(Figure 8). Rare melanoma or possibly cancer-associated variants were found in APC, ARID4A, 
ASXL2, BAP1, BARD1, BCR, BRCA2, CBLB, CDKN2A, EDNRB, ERBB3, ERCC6L2, ERCC8, 
FANCC, FANCF, FANCG, FANCI, MAP3K10, MAP4K3, MC1R, MLH3, OCA2, PML, POLD1, 
POT1, RAD51C, RET, TERT, TET2, XRCC4, XRCC5 (Figure 9). 
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Figure 8. Novel gene variants in individuals with three or more invasive cancers 
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Figure 9. Rare gene variants in individuals with three or more invasive cancers 
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DISCUSSION 
 
Novel and rare variants in families 
 
007178 
 
Four novel segregating mutations were found in this family: MAGI1, MAP4K4, MCC, and ROS1 
(Table 7a). Rare segregating mutations were noted in ERBB3, MAP3K6, EDNRB, and MC1R, as 
well as additional rare mutations in APC, ARID3A, BRCA1, and BRCA2 that did not segregate in all 
four tested family members (Table 7b). None of the five individuals affected by melanoma had any 
other cancer. In other members of the family, a son of the proband developed colorectal cancer 
(Figure 10). 
 
 
 
Figure 10. Pedigree of family 007178. Individuals affected by melanoma (confirmed by criteria 
defined in chapter 3) are shown as filled black symbols, individuals with unconfirmed melanoma 
are shown as filled grey symbols. Males are represented by squares, and females by circles, with 
deceased individuals indicated by a diagonal line. The proband is signified by a black arrow. The 
text under each individual symbol denotes (from top to bottom): individual ID number, age at first 
melanoma diagnosis, and age at death. The above pedigree legend applies to all family pedigrees in 
this chapter. 
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Table 7a: Novel variants of interest in family 007178 
 MAGI1 MAP4K4 MCC ROS1 ASXL1 
007178 nfsins G827S nfsins A2106S Q588X 
018435 nfsins G827S nfsins A2106S WT 
062592 nfsins G827S nfsins A2106S WT 
nfsins: non-frameshift insertion 
 
 
 
Novel segregating variants: 
 
 
MAGI1 
 
MAGI1 codes for proteins that maintain junctional complexes via interaction with PTEN, and which 
play a key role in regulating cell-cell contacts.6 A novel nonframeshift substitution, 
c.3138_3146insCCCAGAGCC, introduces three further amino acids, and the gene has been 
reported as somatically mutated in up to 25% of melanoma tissue samples. Abnormal expression of 
MAGI1 in vitro influences adhesion and invasive potential of cancer cells, and the gene has also 
been associated with colon cancer, small intestine neuroendocrine tumours, hepatocellular 
carcinoma, and primary ALL.6-9 
 
 
MAP4K4 
 
MAP4K4 is involved in cancer cell growth, migration, and apoptosis via downstream effects on 
multiple targets.10 A novel missense mutation, p.Gly827Ser, segregated in this family, and although 
MAPK4K has not specifically been associated with melanoma, the MAPK pathway has been 
consistently linked to melanoma and other cancers. MAP4K4 has been implicated in many different 
cancer types, and overexpression is an independent predictor of poor prognosis for hepatocellular 
carcinoma, lung adenocarcinoma, and colorectal cancer.11-13 It has also been identified as a 
biomarker of prostate cancer aggressiveness, and is associated with laryngeal and lung cancer, via 
regulation of the MAP4K4/JNK apoptosis pathway by SOX2.14, 15 
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MCC 
 
MCC is proposed to act as both a tumour suppressor gene and an oncogene, through diverse 
actions on multiple pathways. Repression or loss of MCC in both liver and colorectal cancer 
influences the "-catenin pathway, where dysregulation leads to unchecked degradation and 
consequent accumulation of oncogenic "-catenin.16 In addition to functioning as a tumour 
suppressor, mouse models have demonstrated that MCC mutations can drive oncogenesis in 
colorectal cancer.17 In contrast to silenced MCC expression in colorectal and liver cancer, 
oncogenic over-expression of MCC has been noted in a range of B cell malignancies, including 
NHL and myeloma.18 The segregating variant in this family, c.44_46insACG, adds an in-frame 
threonine. Although therefore less likely to be deleterious, it is possible that tumour suppressor 
function could be impaired. 
 
 
ROS1 
 
ROS1 is a proto-oncogene that codes for an integral membrane protein with activity as a tyrosine 
kinase, and influences cell proliferation, growth, and survival by likely downstream activation of 
several pathways including PI3K-mTOR signalling. ROS1 impacts cancer development of 
multiple tumour types, and its role as a driver oncogene in glioblastoma and NSCLC has made it a 
promising target for multi-target tyrosine kinase inhibitors.19, 20 The involvement of ROS1 in 
known melanoma pathways, and the presence of the novel segregating missense mutation 
p.Ala2106Ser in the tyrosine kinase domain of ROS1, hints at a likely role for this variant in 
predisposing to melanoma.21 
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Table 7b: Rare variants of interest in family 007178 
Gene: ERBB3 MAP3K6 EDNRB MC1R 
 AA change rs number AA change rs number AA change rs number AA change rs number 
007178 E1196G rs147436223 splicing rs55841735 G57S rs1801710 R142H rs11547464 
018435 E1196G rs147436223 splicing rs55841735 G57S rs1801710 R142H rs11547464 
062592 E1196G rs147436223 splicing rs55841735 G57S rs1801710 WT - 
 
Gene: APC ARID3A BRCA1 BRCA2 
 AA change rs number AA change rs number AA change rs number AA change rs number 
007178 R109W rs139196838 R564Q rs143689585 WT - WT - 
018435 WT - WT - R1300G rs28897689 WT - 
062592 R109W rs139196838 R564Q rs143689585 WT - K3326X  rs11571833 
AA: amino acid, rs: reference SNP 
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Rare segregating variants: 
 
 
ERBB3 
 
ERBB3 encodes for ErbB3, also known as HER3, a membrane bound protein that forms active 
heterodimers with other ErbB receptor tyrosine kinase family members including ErbB2. The 
ErbB2-ErbB3 dimer allows activation of multiple downstream pathways, including the MAPK and 
PI3K/AKT pathways.22 In connection with ErbB2, ErbB3 has been associated with tumour 
proliferation and chemoresistance, as well as disease recurrence and metastasis. The rare missense 
variant p.Glu1196Gly (c.3587A>G, rs147436223) affects the C-terminal binding tail of the 
intracellular domain of ErbB3, and is designated as damaging on both SIFT and PolyPhen2. 
In somatic cancer, the gene product is associated with head and neck SCC, CRC, and breast 
cancer.23, 24 
 
 
MAP3K6 
 
A splicing mutation (rs55841735) was identifed in MAP3K6, which encodes a serine/threonine 
protein kinase that interacts with MAP3K5. The interaction between the two proteins is key in 
regulating downstream pathways due to their opposing effects, where MAP3K6 is a tumour 
suppressor that promotes apoptosis, in contrast to the anti-apoptosis and pro-inflammatory effects 
of MAP3K5. A variety of MAP3K6 germline variants have been identified in families with familial 
gastric cancer, although all variants thus far have been private mutations.25 MAP3K6 may also be 
relevant in skin cancer. A mouse model found that Map3k6 knockout mice develop significantly 
more skin tumours when exposed to an inflammatory stimulus, with an intermediate phenotype for 
heterozygous mice.26   
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EDNRB 
 
The rare missense mutation p.Gly57Ser (rs rs1801710) affects the extracellular domain of the 
EDNRB protein, and was initially identified as a heterozygous variation in a Hirschsprung disease 
(aganglionic megacolon) proband.27 The mutation was inherited from an unaffected carrier, 
suggesting incomplete penetrance, and it is possible that loss of heterozygosity and/or co-modifiers 
are required to express a disease phenotype.27, 28 The mutation has also been seen at low frequency 
in population-based studies, and further in vivo research suggests that the G57S variant impacts the 
cAMP signalling pathway by reduced inhibition of adenylate cyclase.29 While carriers of one 
variant copy of EDNRB may develop Hirschsprung disease, homozygous mutations are associated 
with Waardenburg syndrome type IVa.27 Mutations in EDNRB alter signalling that is crucial for 
development and migration of melanocyte precursors from the neural crest, and the diverse 
phenotypic effects range from the typical white forelock and striking pale blue eye colour seen in 
Waardenburg syndrome, to melanoma.27, 30 Mouse models suggest that decreased EDNRB 
expression transforms benign melanocytic tumour to melanoma, and EDNRB has recently been 
explored as a candidate for targeted therapy, with promising initial in vivo results.31, 32  
EDNRB polymorphisms have not been linked to sporadic melanoma at the population level, 
however a role has been proposed for individuals with a positive melanoma family history.33 A 
family carrying mutations in both CDK4 and in EDNRB has been described, and it is possible that 
epistatic effects influence penetrance.34 
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010482 
 
This 5-case bilineal family can be separated into two family groups – a 3-case family comprising 
the father and his two children, and a 4-case family comprising the mother, her brother, and her two 
children. In the overall group, a number of non-segregating mutations were observed. When 
separated into maternal and paternal bloodlines, some of these mutations segregated in a single 
group. In the 3-case family group, DGKA, DUSP27, and SOX1 variants segregated in all three 
individuals (Table 8a). In the 4-case family group, a PARK7 variant segregated in all four 
individuals. Rare segregating mutations were found in CKAP2 and HUS1 in the 3-case group, and 
in MAP3K11 in the 4-case group (Table 8b). Rare non-segregating mutations were found in APC, 
AXIN1, and MSH6. Additional non-melanoma cancers in this family include prostate cancer in a 
male affected by melanoma (Figure 11). 
 
 
 
 
Figure 11. Pedigree of family 010482 
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Table 8a: Novel variants of interest in bilineal family 010482 
 Overall group 
 CHEK1 DGKA DUSP27 GLI2 PARK7 SOX1 
005977 WT V379I K738E WT A29G nfsins 
010482 WT WT WT G624S A29G WT 
011982 WT V379I K738E G624S A29G nfsins 
022591 F70I V379I K738E WT WT nfsins 
023479 WT WT WT WT A29G WT 
 
  3 case family group  4 case 
  DGKA DUSP27 SOX1  PARK7 
005977  V379I K738E nfsins  A29G 
010482      A29G 
011982  V379I K738E nfsins  A29G 
022591  V379I K738E nfsins   
023479      A29G 
3 case: two affected children and their father; 4 case: two affected children, their mother, and their 
maternal uncle. nfsins: non-frameshift insertion 
 
Novel segregating variants: 
 
DGKA 
 
The novel missense substitution p.Val379Ile (c.1135G>A; NM_001345) in the diacylglycerol 
kinase alpha (DGK!) catalytic domain resultsin a damaging variant that has previously been 
observed as a somatic mutation.21 DGK! phosphorylates diacylglycerol to generate phosphatidic 
acid, thereby regulating the concentration of these two lipid second messengers and their 
downstream effects.35 Proposed effects include cell migration and invasion in a variety of tumour 
types, including breast cancer, glioblastoma, pancreatic cancer, hepatocellular carcinoma, 
lymphoma, and melanoma.36-41 One proposed effect of DGK! in melanoma cells is the specific 
suppression of TNF!-induced apoptosis by catalytic action.41 Given that the V379I mutation 
impacts the catalytic domain, it is plausible that damaging effects may arise due to dysregulated 
apoptosis. Other enzymes in the DGK family have been associated with pigmentation and 
melanogenesis, for example DGK" is implicated in modulation of tyrosinase levels.42 
 
DUSP27 
 
Members of the dual-specificity phosphatase (DUSP) family inactivate target kinases by removing 
phosphates from tyrosine, serine and threonine residues. Downstream signalling of DUSPs impacts 
a variety of MAP kinases, and therefore they have been proposed as novel targets in glioblastoma 
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and breast cancer therapy.43, 44 Specific DUSPs have been associated with other cancers, including 
hepatocellular (DUSP28) and lung (DUSP6) cancer, as well as an in vivo role of DUSP5 as a 
tumour suppressor in skin cancer.45-47 A novel missense mutation was identified in DUSP27 in the 
3-case subgroup of family 010482, at position chr1:167096580 (c.2212A>G; NM_001080426), 
resulting in p.Lys738Glu. In melanoma tumour samples, the somatic mutation frequency of 
DUSP27 ranges from 4-20%.48 Although the effects of DUSP27 are still poorly understood, 
relevance of other DUSPs to cancer suggests that DUSP27 may contribute to similar tumorigenic 
pathways.49, 50 
 
SOX1 
 
The novel variant 1139_1144insCACGCC in SOX1 inserts two extra amino acids, but does not 
induce a frameshift. In melanoma tumour samples, no SOX1 mutations have been reported.21 
However, it is overexpressed in many other cancer cell lines, and it suggested that SOX1 acts as a 
tumour suppressor by interfering with Wnt/#-catenin signalling in cervical cancer, nasopharyngeal 
carcinoma, and hepatocellular carcinoma.51-53 It is also proposed to act as a tumour suppressor in 
NSCLC by regulating actin remodelling in the cytoskeleton, thereby inhibiting cell migration.54 
Although SOX1 may be relevant in other cancers, at this stage the lack of existing melanoma 
mutations and the nonframeshift nature of this variant means that it seems less likely to contribute 
to melanoma in this family. 
 
PARK7 
 
The four case sub-group had a segregating novel missense substitution p.Ala29Gly (c.86C>G) in 
PARK7, which codes for a cancer and Parkinson’s disease related protein that protects cells from 
oxidative stress via multiple pathways.55 PARK7 is overexpressed in a variety of different tumours 
– with clinical impact as a diagnostic or prognostic biomarker in NSCLC, breast cancer, bladder 
cancer, laryngeal SCC, and papillary thyroid cancer, as well as roles in cell differentiation, 
migration, or proliferation in acute leukaemias and pancreatic cancer.55-58 Via interactions with the 
protein BBS1, it has also been associated with mesothelioma.59 Effectors of PARK7 signaling 
include the PI3K/AKT pathway, the MAPK pathway, and p53, and it is possible that mutations in 
PARK7 could drive melanomagenesis through these downstream mechanisms. 
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Table 8b: Rare variants of interest in bilineal family 010482 
 Overall group 
 APC ARID1B AXIN1 BRIP1 MSH6 
 AA rs number AA rs number AA rs number AA rs number AA rs number 
005977 WT  E652D rs139125255 WT  WT  L266V rs2020908 
010482 WT  E652D rs139125255 WT  V193I rs4988346 WT  
011982 S2603C rs72541816 WT  WT  V193I rs4988346 WT  
022591 S2603C rs72541816 WT  WT  WT  L266V rs2020908 
023479 WT  E652D rs139125255 D495E rs146947903 V193I rs4988346 WT  
 
 3 case group 
 CKAP2 HUS1 APC MSH6  
 AA rs number AA rs number AA rs number AA rs number   
005977 E518K rs41292820 D269N rs10253916 WT  L266V rs2020908   
010482           
011982 E518K rs41292820 D269N rs10253916 S2603C rs72541816 WT    
022591 E518K rs41292820 D269N rs10253916 S2603C rs72541816 L266V rs2020908   
023479           
 
 4 case group 
 MAP3K11 ARID1B BRIP1     
 AA Allele frequency AA rs number AA rs number     
005977 C2519T 0.000117 E652D rs139125255 WT      
010482 C2519T 0.000117 E652D rs139125255 V193I rs4988346     
011982 C2519T 0.000117 WT  V193I rs4988346     
022591           
023479 C2519T 0.000117 E652D rs139125255 V193I rs4988346     
3 case: two affected children and their father; 4 case: two affected children, their mother, and their maternal uncle 
AA: amino acid change, rs: reference SNP 
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Rare segregating variants: 
 
CKAP2 
 
The rare missense mutation p.Glu518Lys (c.1552G>A, rs41292820) changes glutamic acid to 
lysine in exon 8 of CKAP2, and is designated as damaging by SIFT and probably damaging by 
PolyPhen2. Although infrequently mutated in melanoma (1-2%), somatic alterations in CKAP2 are 
associated with other cancers, and CKAP2 expression may offer prognostic information for breast 
and liver cancer.48, 60, 61 
 
HUS1 
 
This family had a segregating rare variant p.Asp269Asn (c.805G>A, rs10253916) in HUS1, a gene 
that encodes a checkpoint protein. Hus1, with the other checkpoint sensors Rad9 and Rad1, forms 
the 9-1-1 heterotrimeric complex. This complex is involved in DNA damage repair not only by 
sensing DNA damage, but also via downstream effects on base excision repair.62 HUS1 
polymorphisms have been suggested as low penetrance risk alleles for differentiated thyroid cancer, 
as well as for familial breast and ovarian cancer.63, 64 
 
MAP3K11 
 
The gene product of MAP3K11, MLK3, is a signal integrating kinase that directly phosphorylates 
and activates the JNK pathway, and may also regulate RAF/ERK signalling. A rare variant in 
MAP3K11 (c.2519C>T, p.Pro840Leu) segregated with melanoma in all affected family members. 
Germline MAP3K11 variants have been associated with survival after colon cancer in a case-
control study, and a role for MAP3K11 as a tumour suppressor has been suggested in cell line 
studies of B-cell leukaemia and prostate cancer.65-67 
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012081 
 
Novel segregating mutations were found in SETD5 and TP53BP1, along with non-segregating 
mutations in APC2, MAP3K4, PALB2, and SLX4 (Figure 12, Table 9a, Table 9b). Non-segregating 
mutations were also detected in ANKRD17 and BARD1, which encode BAP1 interacting partners. 
Rare non-segregating mutations were seen in TERT, ARID5A, AXIN2, DNMT3B, and MLH1. 
 
 
 
 
 
Figure 12. Pedigree of family 012081 
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Table 9a: Novel variants of interest in family 012081 
 SETD5 TP53BP1 ANKRD17 BARD1 APC2 MAP3K4 PALB2 SLX4 
007427 L601V nfsins WT S212F WT F495S WT H955P 
012081 L601V nfsins WT WT WT WT L402V WT 
034521 L601V nfsins Q1873R WT R2008G WT WT WT 
nfsins: non-frameshift insertion 
 
 
 
Table 9b: Rare variants of interest in family 012081 
Gene: TERT ARID5A AXIN2 DNMT3B MLH1 
 AA change rs number AA change rs number AA change rs number AA change rs number AA change rs number 
007427 WT  G194E rs150396730 WT  A417V rs116943489 WT  
012081 WT  WT  L662P rs142476324 WT  V647M rs35831931 
034521 V791I rs141425941 G194E rs150396730 WT  WT  V647M rs35831931 
AA: amino acid, rs: reference SNP 
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Novel segregating variants: 
 
SETD5 
 
Although SETD5 has been most consistently associated with intellectual disability, it has also been 
recently identified as a novel biomarker in prostate cancer.68, 69 In a set with four other markers, 
SETD5 has been proposed to enable recognition of aggressive prostate cancer, although by 
unknown mechanisms.68 In melanoma tissue samples, SETD5 has a somatic mutation frequency 
ranging from 4-15%, and is infrequently mutated in tissue samples in the COSMIC database.21, 48 It 
is therefore difficult to determine the possible contribution of the novel missense mutation, 
p.Leu601Val, to melanoma aggregation in this family. 
 
TP53BP1 
 
TP53BP1 mediates DNA double-strand break repair by processing the DNA damage response 
signal and recruiting other repair proteins. A nonframeshift deletion, c.1363_1368delCCTATC, 
segregated in all members of this family, and TP53BP1 has a mutation frequency in melanoma 
ranging from 3-16%.48 While studies on 53BP1 staining in melanoma cells have been 
inconclusive, TP53BP1 expression in thyroid papillary microcarcinoma has been associated with 
BRAF V600E mutation status, a known somatic driver of melanoma.70, 71 TP53BP1 also interacts 
with BRCA1, another gene product linked to melanoma, and reduced expression of TP53BP1 is 
strongly correlated with triple-negative breast cancer and BRCA1-mutated breast cancers.72 Unlike 
the findings in breast cancer, BRCA1-mutated ovarian carcinomas have higher 53BP1 protein 
expression than wildtype cancers.73 Other cancers linked to TP53BP1 include colorectal cancer, 
via effects on cell proliferation and apoptosis, as well as prostate cancer and pancreatic 
adenocarcinoma.69, 74, 75 
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012828 
 
A novel mutation in NEK7 segregated in all four family members affected by melanoma, including 
a male with three other non-melanoma cancers (Figure 13, Table 10a). Non-segregating novel 
mutations were found in ERCC8, MAP3K13, and TBX2, as well as a rare non-segregating mutation 
in ARID4A (Table 10b). Other cancers in this family include prostate, parotid, and breast cancer in a 
male affected by melanoma, NSCLC in his brother who was also affected by melanoma, and CRC 
and lymphoma in their sister. 
 
 
 
Figure 13. Pedigree of family 012828 
 
 
 
Table 10a: Novel variants of interest in family 012828 
 NEK7 ERCC8 MAP3K13 TBX2 
012828 splicing WT WT WT 
029759 splicing WT WT WT 
029760 splicing S138N R385Q WT 
029770 splicing S138N WT G527R 
 
 
Table 10b: Rare variants of interest in family 012828 
Gene: ARID4A BRIP1 
 AA change rs number AA change rs number 
012828 WT  R173C rs4988345 
029759 WT  WT  
029760 splicing rs62621193 WT  
029770 splicing rs62621193 R173C rs4988345 
AA: amino acid, rs: reference SNP 
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NEK7 
 
In this family, a splicing A>G variant of NEK7 segregated in all individuals. NEK7 has not been 
previously associated with melanoma, and is mutated in less than 1% of melanoma tumour 
samples.48  However, it is variably expressed in a number of other tumour types, being 
overexpressed in 10% or more of adrenal, breast, liver, and ovary tissue samples.21 NEK7 has also 
been linked to gallbladder carcinoma differentiation and metastasis.76 The gene product is 
associated with cell cycle control, and along with NEK2 and NEK9, contributes to establishing the 
microtubules of the mitotic spindle for cell division.77 Reduction of NEK7 has been shown to 
arrest cells in mitosis, and therefore has important consequences for cell growth and survival.78  
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013049 
 
No segregating variants were identified in this 6-case family, although novel non-segregating 
mutations in DCC, GNAS, MAP3K1, POLE, RAD52, ROS1, and TET2 were found in some family 
members (Table 11a). POLE has recently been implicated in familial melanoma after a novel 
variant was found in a 7-case melanoma family, and is also proposed to predispose to a wider 
spectrum of cancers.79 Rare non-segregating mutations were found in BRCA1, BRCA2, SOX13, 
SOX4, FANCI, and WWOX (Table 11b). One male affected by melanoma also had prostate cancer 
and mesothelioma, however no sample was available for testing. In first degree relatives of 
melanoma cases, other cancers included lung, prostate, and colorectal cancer (Figure 14). 
 
 
 
 
 
Figure 14. Pedigree of family 013049 
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Table 11a: Novel variants of interest in family 013049 
 DCC GNAS MAP3K1 POLE RAD52 ROS1 TET2 
013049 WT WT WT WT WT WT WT 
026765 G1055S WT WT WT V240G I431V WT 
062740 WT P379L A140S R266Q WT WT WT 
050314 G1055S WT WT WT WT I431V Q526X 
 
 
 
 
Table 11b: Rare variants of interest in family 013049 
Gene: BRCA1 BRCA2 SOX13 
 AA change rs number AA change rs number AA change rs number 
013049 N1189K rs28897687 A2951T rs11571769 R377H rs201772428 
026765 WT  A2951T rs11571769 R377H rs201772428 
062740 WT  WT  WT  
050314 WT  C1151T rs41293475 WT  
 
Gene: SOX4 FANCI WWOX 
 AA change rs number AA change rs number AA change rs number 
013049 WT  WT  WT  
026765 L28V rs140231408 WT  WT  
062740 WT  V1176I - L159F rs186745328 
050314 WT  WT  WT  
AA: amino acid, rs: reference SNP 
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050904 
 
A segregating mutation in ERCC3 was observed, as were segregating rare mutations in ABCB5 and 
MUTYH (Table 12a, Table 12b). Non-segregating mutations were found in SLX4 and NF1 (novel 
variants), and CDKN2A, TP53BP2, and XRCC4 (rare variants). Three melanoma cases were 
affected by additional cancers, including breast cancer, myeloma, and lymphoma (Figure 15). 
 
 
 
 
 
 
Figure 15. Pedigree of family 050904 
 
 
 
 
Table 12a: Novel variants of interest in family 050904 
 ERCC3 SLX4 
030763 fsdel WT 
050904 fsdel R310Q 
063221 fsdel WT 
063222 fsdel WT 
fsdel: frameshift deletion  
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Novel segregating variants: 
 
ERCC3 
 
The ERCC3/XPB gene codes for xeroderma pigmentosum type B (XPB), a DNA helicase that 
contributes to the general transcription factor IIH (TFIIH) complex. It is suggested that XPB acts 
to unwind and hold open strands of DNA to enable nucleotide excision repair, and therefore a 
mutation in this gene may impact the ability of cells to repair DNA damage.80, 81 The variant 
identified in this family, c.1618delA, induces a frameshift from the single nucleotide deletion in 
the ERCC3/RAD25/XPB C-terminal helicase. The frameshift changes the amino acid lysine to 
asparagine at position 540, as well as six subsequent amino acid changes before truncating the 
protein with a TGA opal stop codon at position 547.21 1-5% of melanoma samples have mutations 
in ERCC3, and a handful of rare germline mutations in ERCC3 have been associated with 
xeroderma pigmentosum.48, 82 Previously detected mutations in XPB/ERCC3 include two 
functionally relevant amino acid substitutions and six frameshift/protein truncations, and it is 
possible that the novel frameshift mutation p.Lys540Asn could increase skin cancer susceptibility 
in this family through compromised repair of DNA damage. 
 81 
 
Table 12b: Rare variants of interest in family 050904 
Gene: ABCB5 MUTYH CDKN2A TP53BP2 XRCC4 
 AA change rs number AA change rs number AA change rs number AA change rs number AA change rs number 
30763 splicing rs193255587 G382D rs36053993 G63R rs45456595 R83C rs200028775 L75S rs61762970 
50904 splicing rs193255587 G382D rs36053993 WT  WT  L75S rs61762970 
63221 splicing rs193255587 G382D rs36053993 G63R rs45456595 R83C rs200028775 L75S rs61762970 
63222 splicing rs193255587 G382D rs36053993 G63R rs45456595 WT  WT  
AA: amino acid, rs: reference SNP 
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Rare segregating variants: 
 
ABCB5 
 
ABCB5 encodes for ATP-binding cassette, sub-family B (MDR/TAP), member 5 (ABCB5), a 
plasma protein efflux transporter that helps maintain the cell membrane in a hyperpolarised state.83 
Via these effects on the cell membrane, ABCB5 was initially demonstrated to regulate physiologic 
progenitor cell fusion in melanocytes.83 Beyond its presence at low levels in normal skin, ABCB5 
has also been associated with melanoma. Malignant subpopulations of melanoma-initiating cells 
have been shown to express ABCB5, impacting cell fusion of stem cells and subsequent potential 
for differentiation and progression. A role in immunomodulation has been recently demonstrated, 
where ABCB5 may identify dermal immunoregulatory cells.84 It has also been assessed as a 
biomarker of circulating tumour cells in peripheral blood, and is associated with melanoma 
recurrence.85 Another key effect of ABCB5 expression is chemoresistance. As a multi-drug 
resistance transporter, ABCB5 has the ability to regulate passage of drugs into the cell, and it 
induces resistance to melanoma treatment by the direct efflux of multiple chemotherapy agents.86-
88 Chemoresistance inferred by ABCB5 has been identified in other cancers, namely liver cancer 
and hepatocellular cancer.89-91 A possible role has also been proposed in oral SCC and leukaemia, 
and it is overexpressed in almost a third of sporadic oesophageal cancer.21, 92, 93 The rare 
segregating variant in this family (rs193255587) is a splicing mutation, and the effects of this 
mutation would depend on consequent protein expression and function. 
 
MUTYH 
 
A rare missense mutation in the NUDIX domain of MUTYH was detected (p.Gly382Asp, 
rs36053993), designated as damaging by both SIFT and PolyPhen2. MUTYH is a base excision 
repair gene, with strong links to CRC. While the highest risk of CRC is for carriers of two mutated 
MUTYH alleles, which results in carriers having MUTYH-associated polyposis. CRC risk also 
appears elevated for monoallelic carriers.94 
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051656 
 
Novel variants in MACF1, MX2 and TNK2 segregated in all four melanoma cases, as well as five 
other segregating rare variants in FANCI, PML, SLK, and WWOX (Table 13a, Table 13b). A rare 
segregating variant was also identified in KDM1B, encoding a gene product known to be associated 
with BAP1. Non-segregating novel variants were noted in ERCC3, DCC, ERBB4, and RBL1, and 
non-segregating rare variants in BRCA1 and BUB1. One male first degree relative had bladder 
cancer (Figure 16). 
 
 
 
 
 
Figure 16. Pedigree of family 051656 
 
 
 
 
Table 13a: Novel variants of interest in family 051656 
 MACF1 MX2 TNK2 ERCC3 DCC ERBB4 RBL1 
27711 R415Q R593X P7R WT WT WT C918R 
27715 R415Q R593X P7R fsins A1250T R992H WT 
27716 R415Q R593X P7R fsins A1250T WT WT 
fsins: frameshift insertion   
 
 
 84 
Novel segregating variants: 
 
 
MACF1 
 
MACF1 encodes proteins that are able to form bridges between different cytoskeletal elements, 
and their impact on dynamic microtubule and actin organisation has the capacity to influence cell 
migration, vesicular trafficking, and axonal extension.95 MACF1 mutations have been rarely 
described in cancer, however it has been described in a case of neuroblastoma, where a 
chromosome 1p breakpoint disrupted the gene.96 Additionally, APC-directed recruitment of 
MACF1 to the plasma membrane and subsequent microtubule stability has been implicated in 
breast cancer cell motility.97 MACF1 mutation frequency ranges from 8-14% in cutaneous 
melanoma, and is reported as 40% in desmoplastic melanoma. It is plausible that the p.Arg415Gln 
mutation (c.1244G>A) found in this family may contribute to motility and migration of cancer 
cells.48 
 
 
MX2 
 
The nonsense mutation Arg593* (c.1777C>T) creates a stop codon at the variant site, truncating the 
interferon-induced GTP-binding protein, MX2. MX2 is in the family of large dynamin-like 
GTPases, and in addition to roles in HIV-1 suppression and antiviral activity, it has also been 
connected with melanoma.98-100 The MX2 SNP rs45430 has recently been significantly associated 
with multiple primary melanoma, subsequent to its identification through GWAS in 2011 as a new 
melanoma susceptibility locus.98, 100 As MX2 exerts antiviral activity on HIV-1 through effects on 
nuclear uptake and delaying G(1)/S cell cycle progression, it is plausible that the impact of MX2 
mutation in melanoma may be related to similar processes of cell transport and cell cycle 
regulation.101 
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TNK2 
 
The TNK2 gene (also called ACK1) encodes for a non-receptor tyrosine kinase, activated CDC42 
kinase 1 (ACK1), that is upregulated in many cancers and promotes cancer progression.102 Further 
to its role relaying extracellular signals from RTKs to their intracellular effectors, TNK2/ACK1 has 
been discovered as an epigenic regulator, and has interactions that promote downstream growth of 
gastric cancer, hepatocellular cancer, tamoxifen-resistant breast cancer, leukaemia, and prostate 
cancer.102-105 Overexpression of TNK2/ACK1 has been noted in a range of additional cancers, 
including cervical, ovarian, lung, and upper digestive.21, 48 A novel missense mutation, p.Pro7Arg, 
is found near the start of the sterile ! motif domain of TNK2/ACK1. Although infrequently 
mutated in melanoma tissue samples (3-5%), the range of cancers impacted by TNK2/ACK1 
suggests that the variant may contribute to cellular processes in melanoma progression.48 
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Table 13b: Rare variants of interest in family 051656 
Gene: FANCI KDM1B PML SLK 
 AA change rs number AA change rs number AA change rs number AA change rs number 
27711 T824C rs142906652 S252P rs138145635 Q668R rs140648301 E821K rs140813954 
27715 T824C rs142906652 S252P rs138145635 Q668R rs140648301 E821K rs140813954 
27716 T824C rs142906652 S252P rs138145635 Q668R rs140648301 E821K rs140813954 
 
Gene: WWOX BRCA1 BUB1 
 AA change rs number AA change AA change rs number AA change 
27711 R7W rs141361080 S1465I rs1800744 A206V rs61730706 
27715 R7W rs141361080 WT    
27716 R7W rs141361080 WT     
AA: amino acid, rs: reference SNP 
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Rare segregating variants: 
 
FANCI 
 
A missense mutation in FANCI, p.Ile275Thr (rs142906652), segregated in all family members, and 
was designated as damaging by both SIFT and PolyPhen2. FANCI is part of the Fanconi anaemia 
complementation group, comprising multiple genes associated with DNA repair. Partnered activity 
of FANCI and BRCA1 (also known as FANCD2) has an essential role in DNA damage repair, 
however it has recently been suggested that FANCI alone is sufficient for formation of Fanconi 
anaemia core complex foci.106 Although its independent effects mean it is less likely to be 
a BRCA1 phenocopy, deleterious germline mutations in FANCI have been noted in breast cancer.107 
 
KDM1B 
 
The KDM1B gene product interacts with BAP1, and thus the segregating rare missense mutation 
p.Ser252Pro (rs138145635) in KDM1B may contribute to a cancer phenotype reminiscent of that 
seen in families with mutated BAP1. The protein is a histone lysine demethylase, and is part of a 
subnetwork that overlaps the BAP1 complex.108 Interestingly, a rare non-segregating mutation in 
BRCA1 was also noted in this family. 
 
PML 
 
A segregating missense mutation p.Gln668Arg (rs140648301) was found in PML, a gene located 
at 15q24.1 that encodes the PML tumour suppressor protein. PML is a key component of dynamic 
nuclear structures termed PML-nuclear bodies, which function as regulators of transcription, cell 
cycle control, DNA damage response, and apoptosis. The implication of disrupted PML is 
demonstrated by the t(15;17) translocation of acute promyelocyctic leukaemia (APL), generating 
the consequent oncogenic fusion protein PML-retinoic acid receptor-alpha.109 Studies in mice 
assessing the relationship between mutated p53 and PML found enhanced accumulation of mutant 
p53 in the absence of PML, accompanied by development of lymphomas and sarcomas.109 Loss of 
PML function via a damaging mutation like p.Gln668Arg may therefore promote oncogenesis by 
removing the brakes from other ‘gain of function’ mutations. 
 
 
 
 88 
SLK 
 
SLK encodes for the Ste20-like kinase SLK, a serine/threonine protein kinase that mediates 
apoptosis and may impact cell migration via effects on cytoskeleton disassembly.110 SLK is 
expressed in a range of normal tissue, and has also been identified as a downstream effector of 
chemotaxis in ErbB2 activated breast cancer cell lines. It is possible that the segregating missense 
mutation p.Glu821Lys (rs140813954) could add to polygenic risk in conjunction with the multiple 
additional mutations in this family. 
 
WWOX 
 
WWOX spans the common chromosomal fragile site FRA16D, a region of chromosomal instability 
that is particularly sensitive to replicative stress. Consistent with other genes located at fragile 
sites, WWOX has been recognised as a tumour suppressor gene, and its loss has effects on multiple 
signalling pathways including DNA damage response and apoptosis. Cancer associations for 
germline WWOX variants include susceptibility to prostate cancer, progression of head and neck 
cancers, and overall survival in pancreatic cancer.111-113 A potential role has also been recognised 
in myeloma, where loss of heterozygosity at the location of WWOX, 16q23, led to reduced WWOX 
expression and worse overall survival.114 In this family, a missense mutation in WWOX 
(p.Arg7Trp, rs141361080) was found to be damaging by both SIFT and PolyPhen2. Although this 
gene has not previously associated with melanoma, links with tumour progression in multiple other 
cancers may hint at a potential pleiotropic effect. 
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052448 
 
Three segregating mutations were found in this family: a novel variant in GRIN2C, and two 
different rare variants in TYRP1 that may represent a single haplotype (Figure 17, Table 14a, Table 
14b). A novel non-segregating mutation was found in ASXL2, encoding a BRCA1-associated 
protein in addition to non-segregating novel variants in ALK, ARID3A, ARID4B, DGKB, JAK2, 
MLH3. 
 
 
 
 
 
 
Figure 17. Pedigree of family 052448 
 
 
 
 
 
Table 14a: Novel variants of interest in family 052448 
 GRIN2C ALK ARID3A ARID4B ASXL2 DGKB JAK2 MLH3 
27520 nfsins D1141N A429T nfsdel WT WT H891Y R1152C 
52448 nfsins WT A429T WT W213R V98I WT R1152C 
63258 nfsins D1141N WT WT WT V98I WT WT 
nfsdel: non-frameshift deletion, nfsins: non-frameshift insertion 
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Novel segregating variants: 
 
GRIN2C 
 
GRIN2C encodes the glutamate (NMDA) receptor subunit NMDAR2C, and the nonframeshift 
insertion c.3138_3146insCCCAGAGCC results in an additional three amino acids. Mutations in 
this gene have previously been associated with neuromuscular effects, and mutation frequency in 
melanoma ranges from 2-8%.48 A paralog, GRIN2A, has been identified as frequently mutated in 
melanoma, however it is possibly due to divergent effects on downstream MAPK signalling rather 
than a shared mechanism with GRIN2C (Wei 2011, Willard 2013).115, 116 
 
 
Table 14b: Rare variants of interest in family 052448 
Gene: TYRP1 TYRP1 
 AA change rs number AA change rs number 
27520 A24T rs61758405 R153C rs146027807 
52448 A24T rs61758405 R153C rs146027807 
63258 A24T rs61758405 R153C rs146027807 
AA: amino acid, rs: reference SNP 
 
 
Rare segregating variants: 
 
TYRP1 
 
Two rare damaging TYRP1 variants segregated in this family, p.Ala24Thr (rs61758405) and 
p.Arg153Cys (rs146027807), inferring a bi-allelic haplotype. TYRP1 has important functions in 
melanin synthesis and also in maintaining stability of the tyrosinase protein. The spectrum of 
mutation phenotype ranges from oculocutaneous albinism and Melanesian blonde hair in those 
with homozygous or compound heterozygous TYRP1 mutations, to fairer skin, eye, and hair 
colour in heterozygous carriers.117, 118 Similar to MC1R, ASIP, and TYR polymorphisms, some 
variants in TYRP1 are associated with fair pigmentation phenotypes, and have been associated with 
cutaneous melanoma.119-121 Several TYRP1 germline variants have recently been associated with 
multiple primary melanoma.100  
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BAP1 phenocopies 
 
Further to the genes above, a number of variants were identified in genes that encode products 
which interact with that of the known melanoma predisposition gene, BAP1. The tumour suppressor 
function of BAP1 is in part due to ubiquination, mediated by coordinated activity between BAP1 
and the BRCA1/BARD1 complex.122 The integration of multiple proteins is evident from studies in 
mice, where BARD1 deficiency led to phenotypes similar to those expressed in BRCA1 mutations. 
A novel BARD1 mutation was noted in family 012081, in addition to BRCA1 and BRCA2 variants 
in family 007178 and 013049.  BAP1 also has links with ASXL1, where together they form the 
Polycomb group repressive deubiquitinase complex.123 Cell senescence is also regulated by an 
interaction with ASXL2, although ASXL1 appears more deleterious when mutated.124 A novel 
ASXL1 variant was detected in family 007178, and in addition to possible melanoma predisposition, 
mutations in ASXL1 have been significantly associated with haematological malignancies. 
ANKRD17 and KDM1B are also associated with the BAP1 complex, and mutations in these genes 
were found in family 012081 and 051656 respectively, with the KDM1B mutation segregating in all 
family members.108 Through their interactions with BAP1, it is proposed that these associated genes 
impact similar pathways, and thus a mutation in one of these genes may have the same phenotypic 
outcome as BAP1 mutations in predisposing to melanoma and other cancers. 
 
Excluded variants 
 
Variants with counts higher than the number of affected members in each family were excluded, to 
account for the possibility of these variants representing copy errors rather than a true mutation. 
Excluded variants were ARID1B, GNAL, KISS1, MNT, and XRCC1. ARID1B variants were 
observed in many families, with some variants appearing to segregate or partially segregate. Due to 
the number of ARID1B variants we have excluded this variant due to the possibility of copy errors. 
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Novel and rare variants in individuals with three or more cancer types 
 
Four females and seven males with three or more invasive cancers including melanoma had DNA 
samples available for sequencing (Table 15). 
 
Table 15   Results of next generation sequencing for individuals affected by melanoma and at least 
two other invasive cancers 
Family Indiv 
ID 
Seq Cancers in order 
of diagnosis 
Novel variants Rare variants 
Females 
005921 031531 WES Melanoma, CLL, 
NHL 
MAP3K1, 
MAP3K13, MAP3K4 
BRCA2, FANCC 
011734 001043 WES Melanoma x 4, 
Endometrial, 
Thyroid 
APC, MAGI1, NEK4 MC1R, RET 
050657 050657 WGS Melanoma, 
Myeloma, CML 
ALK, FANCD2 ASXL2, BAP1, CDKN2A, 
FANCC, FANCG, 
MAP3K10, 
MAP4K3, TERT 
 
050904 050904 WGS Melanoma, 
Breast, Myeloma 
APC, ERCC3, 
MAP3K4, MSH2, 
NF1, POLD1, SLX4 
APC, BARD1, CBLB, 
ERBB3, MLH3, OCA2, 
POLD1, RAD51C, RET, 
XRCC4 
Males 
002145 016018 WES Thyroid, 
Melanoma, RCC 
MAP2K3, MAP3K4, 
MAP3K6 
(none) 
003091 003091 WES RCC, Prostate, 
Melanoma 
FANCA, FANCC FANCI, MAP3K10, 
MAP4K3, RAD51C, 
TET2 
009782 009782 WES Melanoma, CRC, 
AML 
APC, ARID5B, 
PLK5, TET2, 
TP53AIP1 
BARD1, BCR, CBLB, 
EDNRB, FANCC, TET2 
012828 029760 WES Prostate, Breast, 
Parotid, 
Melanoma 
MAGI1, MAP3K13, 
MAP3K5, NEK7, 
PLK5 
ARID4A 
013398 013398 WGS Melanoma, NHL, 
RCC, CRC, 
Prostate 
CDH1, ETV5, 
MAP3K4, POLD1 
FANCC, FANCF, PML, 
POT1 
050492 050492 WGS Melanoma, 
Prostate, NHL, 
CLL 
CDH1, IDH1 ERCC6L2, ERCC8, 
XRCC5 
050695 050695 WGS Melanoma x4, 
CRC, Gallbladder 
ARID3B, MC1R, 
MTAP 
(none) 
Indiv ID: individual ID, Seq: sequencing, AML: acute myeloid leukaemia; CLL: chronic lymphocytic 
leukaemia; CML: chronic myeloid leukaemia; CRC: colorectal cancer; NHL: non-Hodgkin lymphoma; 
RCC: renal cell carcinoma, WES: whole exome sequencing, WGS: whole genome sequencing. 
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Females 
 
031531 
A rare BRCA2 variant and two frameshift mutations in MAPK pathway genes may have contributed 
to melanoma in this female, who subsequently developed CLL and NHL. Further to established 
BRCA2 associations, the presence of a mutation in this gene may be particularly significant for this 
female due to a potential role for certain BRCA2 variants in CLL predisposition.125 
 
001043 
This female was affected by multiple melanomas, and it is possible that a mutation in MC1R 
contributed to her developing four primary melanomas. She also had endometrial and thyroid 
cancer, and was found to carry mutations in two genes strongly associated with familial cancer – 
RET and APC. Germline mutations in the proto-oncogene RET are key to development and 
progression of familial medullary thyroid cancer, and it is proposed that low penetrance SNPs in 
this gene could also contribute to sporadic medullary thyroid cancer.126 APC is also linked to 
multiple sporadic cancers, as well as familial adenomatous polyposis coli syndrome. 
 
050904 
This female with breast cancer and myeloma harboured mutations in several genes known to be 
associated with cancer, including a gene linked with breast cancer. Germline mutations in RAD51C 
have been identified in a small number of families with breast and/or ovarian cancer, and given 
existing associations between these cancers and melanoma for other genes, it is plausible that 
melanoma could be a pleiotropic effect of a germline mutation in RAD51C.127 Her sister was also 
affected by both breast cancer and melanoma. Mutations in a number of genes linked with CRC 
susceptibility were identified (APC, POLD1, MLH3) as well as variants involved in DNA repair 
(SLX4, XRCC4). A novel frameshift mutation in ERCC3 segregated in all melanoma affected 
members of her family, and it is possible that impaired DNA repair caused by the truncated gene 
product influenced oncogenesis. A non-segregating rare variant in CDKN2A was identified in her 
three relatives with melanoma, however she did not carry the mutation. 
 
050657 
This female was found to carry mutations in the high penetrance melanoma risk genes BAP1, 
CDKN2A, and TERT, as well as additional variants in genes related to Fanconi anaemia and MAPK 
pathways. While the presence of mutated BAP1, CDKN2A, and TERT certainly suggests a possible 
basis for her melanoma susceptibility, the presence of an ALK mutation is interesting in light of her 
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additional haematological cancers - myeloma and CML. Somatic mutations of ALK are associated 
with lymphoma, and expression of a novel ALK transcript from a de novo alternative transcript 
initiation site in intron 9 has recently been described in approximately 10% of melanomas.128 
 
Males 
 
016018 
Following thyroid cancer, this male developed melanoma and RCC, however relatively few 
mutations in cancer genes were identified. He carried mutations in three MAPK pathway genes, 
including a MAP3K4 frameshift variant, and these may have partially contributed to his cancer 
development. 
 
003091 
This male had RCC and prostate cancer, prior to developing melanoma. Sequencing demonstrated 
variants in DNA repair genes associated with the Fanconi anaemia pathway, which is implicated in 
melanoma as well as a diverse range of other cancers.129, 130 A nonsense mutation was identified in 
FANCC, further to SNVs in FANCA, FANCI, and RAD51C. 
 
009782 
Although no melanoma predisposition gene variants were identified in this individual, a frameshift 
mutation in TP53AIP1 may be significant in melanoma risk due to its likely role in mediating p53-
dependent apoptosis. A BARD1 mutation may also be significant, due to its function in mitotic 
spindle-pole assembly in conjunction with BRCA1. He additionally had a nonsynonymous SNV in 
APC, a gene associated with CRC, and a nonsynonymous SNV in BCR, which is associated 
somatically with ALL and CML via breakpoints in this gene that facilitate Philadelphia 
chromosome translocation. A frameshift mutation in TET2 may have influenced the development of 
AML in this man, as somatic TET2 mutations have been linked with myelodysplastic syndromes 
and leukaemias.131 Although his sisters were not sequenced for possible mutations, development of 
breast cancer and CRC in one sister, and myeloma and melanoma in the other may have been 
influenced by the above variants. 
 
029760 
A diverse spectrum of cancers including melanoma, prostate, breast, and parotid cancer developed 
in this male, however few candidate predisposition genes were identified on sequencing. He carried 
mutations in two genes impacting cell cycle control – a segregating splicing variant in NEK7, and a 
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SNV in PLK5. PLK5 has been identified as a potential tumour suppressor, due to silencing in 
astrocytoma and glioblastoma multiforme. He also had a splicing variant in ARID4A, which may 
have influenced melanoma development via effects of the gene product on retinoblastoma protein 
and subsequent cell proliferation. Of particular interest is his breast cancer, given the rarity of this 
cancer in males. No BRCA2 or BRCA1 mutations were identified, nor mutations in any genes 
known to interact with BRCA1/2. 
 
013398 
Five invasive cancers affected this male – melanoma, NHL, RCC, CRC, and prostate cancer. A 
strong familial component to cancer development is suggested by the presence of multiple cancers 
in his father, who was affected by two primary melanomas, Hodgkin lymphoma, and CML. It 
would be interesting to assess for potential shared germline variants in a father and son with an 
exceptionally high number of cancers, however his father had passed away and did not have any 
available DNA for sequencing. Mutations in two Fanconi anaemia pathway genes were noted, as 
well as mutations in POT1 and POLD1. It is plausible that the variant in POT1, a known high 
penetrance melanoma susceptibility gene with links to other cancers, predisposed to a wider range 
of tumour types in this male and possibly also his father. The POLD1 mutation may have 
contributed to an underlying CRC susceptibility. He also was found to carry mutated PML, a gene 
associated with acute promyelocytic leukaemia, which has also been tentatively linked to CML 
development.132 
 
050492 
This male had melanoma, prostate cancer, NHL, and CLL. Prostate cancer susceptibility has been 
suggested for carriers of a particular CDH1 allele, and the gene has been implicated in hereditary 
diffuse gastric cancer and hereditary lobular breast cancer.133-135 It is possible that this man’s 
p.Pro6Arg mutation in CDH1 contributed in a pleitropic manner to the development of multiple 
cancers. 
 
050695 
In addition to four primary melanomas, this man also had CRC and gallbladder cancer. A novel 
mutation in MTAP was noted, a gene located close to CDKN2A on chromosome 9p21.  
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Contribution of polygenic risk 
 
For families with a high case density of melanoma, there were no segregating mutations in known 
high penetrance melanoma predisposition genes. As discussed in Chapter 2, a large proportion of 
melanoma families do not carry known risk genes, and therefore the balance of genetic 
susceptibility is proposed to fall almost entirely to a combination of low to moderate effect 
polymorphisms. Although it is unlikely that a SNP with low penetrance would alone lead to cancer, 
the combination of multiple risk SNPs in predictive models has promising ability to refine risk 
prediction in conjunction with pigmentation phenotype.136 Beyond risk prediction, some melanoma 
loci have been implicated as novel biomarkers of melanoma recurrence and overall survival.130, 137 
The diverse phenotypes and different cancer ‘syndromes’ associated with particular ‘melanoma’ 
risk genes such as BAP1 suggests a degree of pleiotropy, and hints at common pathways to 
oncogenesis. A recent study assessed 181 cancer-associated GWAS SNPs for possible risk 
associations with melanoma, and identified a pleiotropic effect for two lung cancer SNPs, and a 
male-specific effect for a prostate cancer SNP.138 Given the wide range of genetic variants and also 
other cancer types in the cohort, it is plausible that some cancer-associated genes identified here 
also have pleiotropic effects in predisposing to melanoma.  
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Chapter 5 
 
Conclusion 
 
Heritable melanoma risk is complex – comprised of possible known high penetrance genes, but 
more likely a mélange of low to moderate penetrance polymorphisms and co-modifiers that impact 
multiple pathways, each contributing to cancer in a small way with devastating impact when 
summated.  
 
An over-representation in some cancer types detailed in chapter 3, coupled with the variety of 
cancer-associated genes identified in some families and individuals in chapter 4, hints at the 
possibility of common pathways for oncogenesis and pleiotropic effects for melanoma and cancer-
associated risk genes. 
 
Variable penetrance and rarity at the population level present challenges for the clinical application 
of familial cancer genetics. However, combination of novel SNPs in polygenic risk estimates has 
promising application in delineating disease risk and providing more sensitive estimates of 
prognosis. In melanoma, it is plausible that knowing of an unfavourable germline variant or set of 
variants may alter surveillance frequency and direct treatment choices toward a more aggressive 
approach at an earlier date, and improve clinical outcomes. It is also possible that novel variants 
predisposing to melanoma could identify pathways that may be amenable to targeted therapy in 
sporadic melanoma.  
 
Overall, multiple genes and environmental modifiers likely modulate melanoma risk. In this cohort 
of Queensland ‘intermediate risk’ melanoma families, increased risk of some cancers has been 
identified at a population level, as well as numerous genes of interest in families with high case 
density and individuals with multiple cancers. Compared to the general cohort, it is interesting that 
some high case density families had few other cancers, whereas other high case density families had 
multiple additional tumour types including individuals with three or more different kinds of 
invasive cancer. Different sets of risk genes are likely to cause variable phenotypic expression, and 
also may be influenced by variable penetrance for different tumour types. The novel and rare 
segregating variants identified here in cancer-associated genes present promising candidate 
polymorphisms for familial melanoma.
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Appendix A: Novel segregating variants 
 
AnnoGene Family N fam N var chr position AnnoRegion AnnoRefSeq AnnoType AnnoNTchange AnnoAAchange AnnoExon 
DGKA 010482_3 5 3 12 56335069 exonic NM_001345 nonsynonymous SNV G1135A V379I 14 
DUSP27 010482_3 5 3 1 167096580 exonic NM_001080426 nonsynonymous SNV A2212G K738E 5 
ERCC3 050904 4 4 2 128036858 exonic NM_000122 frameshift substitution 1618_1621AAT 10 
GRIN2C 052448 3 3 17 72839135 exonic NM_000835 nonframeshift substitution 3138_3141CCCAGAGCCCCCG 13 
MAGI1 007178 3 3 3 65425567 exonic NM_001033057 nonframeshift substitution 1255_1257CATCAG 9 
MAP4K4 007178 3 3 2 102488007 exonic NM_145686 nonsynonymous SNV G2479A G827S 22 
MCC 007178 3 3 5 112824068 exonic NM_001085377 nonframeshift substitution 44_44delinsACGG 1 
MX2 051656 3 3 21 42778797 exonic NM_002463 stopgain C1777T R593X 13 
NEK7 012828 4 4 1 198222168 splicing       
PARK7 010482_4 5 4 1 8022931 exonic NM_001123377 nonsynonymous SNV C86G A29G 2 
ROS1 007178 3 3 6 117631362 exonic NM_002944 nonsynonymous SNV G6316T A2106S 40 
SETD5 012081 3 3 3 9489388 exonic NM_001080517 nonsynonymous SNV C1801G L601V 15 
SOX1 010482_3 5 3 13 112723111 exonic NM_005986 nonframeshift substitution 1139_1146CGGGCGTGGGCGTG 1 
TP53BP1 012081 3 3 15 43762077 exonic NM_001141979 nonframeshift substitution 1360_1368CCA 11 
MACF1 051656 3 3 1 39750852 exonic NM_012090 nonsynonymous SNV G1244A R415Q 11 
TNK2 051656 3 3 3 195622268 exonic NM_001010938 nonsynonymous SNV C20G P7R 1 
 
N fam: number of individuals in the family. N seq: number of individuals sequenced. N var: number of variants identified in data set. Chr: chromosome. AnnoRegion: Genomic 
region as annotated by annovar. AnnoRefSeq: efSeq ID as annotated by annovar. AnnoType: Effect of mutation such as synonymous, nonsynonymous. AnnoNTchange: Nucleotide 
base change, AnnoAAchange: Amino Acid Change, AnnoExon: Exon number in transcript, SNV: single nucleotide variant.
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Appendix B: Novel non-segregating variants 
 
AnnoGene Family N fam N var chr position AnnoRegion AnnoRefSeq AnnoType AnnoNTchange AnnoAAchange AnnoExon 
ALK 052448 3 2 2 29445412 exonic NM_004304 nonsynonymous SNV G3421A D1141N 21 
ANKRD17 012081 3 1 4 73956974 exonic NM_198889 nonsynonymous SNV A5618G Q1873R 28 
APC2 012081 3 1 19 1469322 exonic NM_005883 nonsynonymous SNV C6022G R2008G 15 
ARID3A 052448 3 2 19 966658 exonic NM_005224 nonsynonymous SNV G1285A A429T 7 
ARID4B 052448 3 1 1 235377278 exonic NM_001206794 nonframeshift substitution 1630_1647GAGGAGGAGGAGGAA 17 
ASXL1 007178 3 1 20 31022277 exonic NM_015338 stopgain C1762T Q588X 12 
ASXL2 052448 3 1 2 25990590 exonic NM_018263 nonsynonymous SNV T637C W213R 7 
BARD1 012081 3 1 2 215645906 exonic NM_001282543 nonsynonymous SNV C635T S212F 3 
CHEK1 010482 5 1 11 125497644 exonic NM_001114121 nonsynonymous SNV T208A F70I 3 
DCC 013049 4 2 18 50942526 exonic NM_005215 nonsynonymous SNV G3163A G1055S 21 
DCC 051656 3 2 18 51013178 exonic NM_005215 nonsynonymous SNV G3748A A1250T 26 
DGKB 052448 3 2 7 14775696 exonic NM_004080 nonsynonymous SNV G292A V98I 4 
ERBB4 051656 3 1 2 212285326 exonic NM_001042599 nonsynonymous SNV G2975A R992H 25 
ERCC3 051656 3 2 2 128038128 exonic NM_000122 frameshift substitution 1421_1422AAT 9 
ERCC8 012828 4 2 5 60186885 exonic NM_001290285 nonsynonymous SNV G413A S138N 9 
GLI2 010482 5 2 2 121742233 exonic NM_005270 nonsynonymous SNV G1870A G624S 11 
GNAS 013049 4 1 20 57429643 exonic NM_001077490 nonsynonymous SNV C1136T P379L 1 
JAK2 052448 3 1 9 5054748 exonic NM_004972 nonsynonymous SNV C800G T267R 7 
JAK2 052448 3 1 9 5089773 exonic NM_004972 nonsynonymous SNV C2671T H891Y 20 
MAP3K1 013049 4 1 5 56111817 exonic NM_005921 nonsynonymous DNV 417_418GT AA139_140AS 1 
MAP3K13 012828 4 1 3 185190894 exonic NM_001242317 nonsynonymous SNV G1154A R385Q 10 
MAP3K4 012081 3 1 6 161512562 exonic NM_001291958 nonsynonymous SNV T1484C F495S 13 
MLH3 052448 3 2 14 75508329 exonic NM_001040108 nonsynonymous SNV C3454T R1152C 4 
NF1 050904 4 3 17 29653223 exonic NM_000267 nonsynonymous SNV C5158A H1720N 36 
PALB2 012081 3 1 16 23646663 exonic NM_024675 nonsynonymous SNV C1204G L402V 4 
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POLE 013049 4 1 12 133253953 exonic NM_006231 nonsynonymous SNV G797A R266Q 8 
RAD52 013049 4 1 12 1023614 exonic NM_001297421 nonsynonymous SNV T719G V240G 8 
RBL1 051656 3 1 20 35635933 exonic NM_002895 nonsynonymous SNV T2752C C918R 20 
ROS1 013049 4 2 6 117710981 exonic NM_002944 nonsynonymous SNV A1291G I431V 12 
SLX4 012081 3 1 16 3640775 exonic NM_032444 nonsynonymous SNV A2864C H955P 12 
SLX4 050904 4 1 16 3652140 exonic NM_032444 nonsynonymous SNV G929A R310Q 4 
TBX2 012828 4 1 17 59483090 exonic NM_005994 nonsynonymous SNV G1579A G527R 6 
TET2 013049 4 1 4 106156675 exonic NM_001127208 stopgain C1576T Q526X 3 
 
N fam: number of individuals in the family. N seq: number of individuals sequenced. N var: number of variants identified in data set. Chr: chromosome. AnnoRegion: Genomic 
region as annotated by annovar. AnnoRefSeq: efSeq ID as annotated by annovar. AnnoType: Effect of mutation such as synonymous, nonsynonymous. AnnoNTchange: Nucleotide 
base change, AnnoAAchange: Amino Acid Change, AnnoExon: Exon number in transcript, SNV: single nucleotide variant. 
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Appendix C: Rare segregating variants 
 
AnnoGene Family N fam N var chr position AnnoRegion AnnoRefSeq AnnoType AnnoNTchange AnnoAAchange AnnoExon 
ABCB5 050904 4 4 7 20691041 splicing      
EDNRB 007178 3 3 13 78492540 exonic NM_001122659 nonsynonymous SNV G169A G57S 1 
ERBB3 007178 3 3 12 56495397 exonic NM_001982 nonsynonymous SNV A3587G E1196G 28 
FANCI 051656 3 3 15 89811698 exonic NM_001113378 nonsynonymous SNV T824C I275T 10 
KDM1B 051656 3 3 6 18197821 exonic NM_153042 nonsynonymous SNV T754C S252P 10 
MAP3K6 007178 3 3 1 27688743 splicing      
MUTYH 050904 4 4 1 45797228 exonic NM_001048171 nonsynonymous SNV G1145A G382D 13 
PML 051656 3 3 15 74327949 exonic NM_033250 nonsynonymous SNV A2003G Q668R 7 
SLK 051656 3 3 10 105765430 exonic NM_014720 nonsynonymous SNV G2461A E821K 10 
TYRP1 052448 3 3 9 12694066 exonic NM_000550 nonsynonymous SNV G70A A24T 2 
TYRP1 052448 3 3 9 12695586 exonic NM_000550 nonsynonymous SNV C457T R153C 3 
WWOX 051656 3 3 16 78149000 exonic NM_001291997 nonsynonymous SNV C19T R7W 3 
MAP3K11 010482_4 5 4 11 65365787 exonic NM_002419 nonsynonymous SNV C2519T P840L 10 
CKAP2 010482_3 5 3 13 53047966 exonic NM_001098525 nonsynonymous SNV G1552A E518K 8 
HUS1 010482_3 5 3 7 48004991 exonic NM_004507 nonsynonymous SNV G805A D269N 8 
 
N fam: number of individuals in the family. N seq: number of individuals sequenced. N var: number of variants identified in data set. Chr: chromosome. AnnoRegion: Genomic 
region as annotated by annovar. AnnoRefSeq: efSeq ID as annotated by annovar. AnnoType: Effect of mutation such as synonymous, nonsynonymous. AnnoNTchange: Nucleotide 
base change, AnnoAAchange: Amino Acid Change, AnnoExon: Exon number in transcript, SNV: single nucleotide variant. 
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Appendix D: Rare non-segregating variants 
 
AnnoGene Family N fam N var chr position AnnoRegion AnnoRefSeq AnnoType AnnoNTchange AnnoAAchange AnnoExon 
APC 007178 3 2 5 112102960 exonic NM_001127511 nonsynonymous SNV C325T R109W 3 
APC 010482 5 2 5 112179153 exonic NM_001127511 nonsynonymous SNV C7808G S2603C 14 
ARID3A 007178 3 2 19 971974 exonic NM_005224 nonsynonymous SNV G1691A R564Q 9 
ARID4A 012828 4 2 14 58832019 splicing       
ARID5A 012081 3 2 2 97216846 exonic NM_212481 nonsynonymous SNV G581A G194E 7 
AXIN1 010482 5 1 16 348021 exonic NM_003502 nonsynonymous SNV C1485G D495E 6 
AXIN2 012081 3 1 17 63532594 exonic NM_004655 nonsynonymous SNV T1985C L662P 8 
BRCA1 007178 3 1 17 41243509 exonic NM_007297 nonsynonymous SNV A3898G R1300G 9 
BRCA1 051656 3 1 17 41226488 exonic NM_007297 nonsynonymous SNV G4394T S1465I 13 
BRCA1 013049 4 1 17 41243840 exonic  nonsynonymous SNV N1189K 9 
BRCA2 013049 4 2 13 32953550 exonic  nonsynonymous SNV A2951T 10 
BRCA2 013049 4 1 13 32906766 exonic  nonsynonymous SNV C1151T 22 
BRCA2 007178 3 1 13 32972626 exonic NM_000059 stopgain A9976T K3326X 27 
BRIP1 010482_4 5 3 17 59924512 exonic NM_032043 nonsynonymous SNV G577A V193I 6 
BRIP1 012828 4 2 17 59924572 exonic NM_032043 nonsynonymous SNV C517T R173C 6 
BUB1 051656 3 2 2 111425226 exonic NM_001278616 nonsynonymous SNV C617T A206V 7 
CDKN2A 050904 4 3 9 21974640 exonic NM_058197 nonsynonymous SNV G187C G63R 1 
DNMT3B 012081 3 1 20 31386313 exonic NM_001207056 nonsynonymous SNV C1250T A417V 12 
FANCI 013049 4 1 15 89856189 exonic NM_018193 nonsynonymous SNV G3526A V1176I 34 
MAP3K12 050904 4 3 12 53876569 exonic NM_001193511 nonsynonymous SNV G2018A G673D 11 
MAP3K6 007178 3 3 1 27688743 splicing       
MC1R 007178 3 2 16 89986091 exonic NM_002386 nonsynonymous SNV G425A R142H 1 
MLH1 012081 3 2 3 37092019 exonic NM_001258271 nonsynonymous SNV G1939A V647M 17 
MSH6 010482_3 5 2 2 48026308 exonic NM_001281492 nonsynonymous SNV C796G L266V 2 
SOX13 013049 4 2 1 204092087 exonic NM_005686 nonsynonymous SNV G1130A R377H 10 
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SOX4 013049 4 1 6 21594847 exonic NM_003107 nonsynonymous SNV C82G L28V 1 
TERT 012081 3 1 5 1272311 exonic NM_001193376 nonsynonymous SNV G2371A V791I 7 
TP53BP2 050904 4 2 1 224001984 exonic NM_001031685 nonsynonymous SNV C247T R83C 3 
WWOX 013049 4 1 16 78466409 exonic NM_001291997 nonsynonymous SNV G477T L159F 7 
XRCC4 050904 4 3 5 82406931 exonic NM_003401 nonsynonymous SNV T224C L75S 3 
 
N fam: number of individuals in the family. N seq: number of individuals sequenced. N var: number of variants identified in data set. Chr: chromosome. AnnoRegion: Genomic 
region as annotated by annovar. AnnoRefSeq: efSeq ID as annotated by annovar. AnnoType: Effect of mutation such as synonymous, nonsynonymous. AnnoNTchange: Nucleotide 
base change, AnnoAAchange: Amino Acid Change, AnnoExon: Exon number in transcript, SNV: single nucleotide variant. 
 
